Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
48 "Jee Hyun Kim"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Article
Pilot Study for Feasibility of Onco-Geriatric Intervention Model in Older Patients with Cancer in a Tertiary Academic Hospital
Jin Won Kim, Jung-Yeon Choi, Woochan Park, Minsu Kang, Jeongmin Seo, Eun Hee Jung, Koung Jin Suh, Ji-Won Kim, Se Hyun Kim, Yu Jung Kim, Keun-Wook Lee, Sang-A Kim, Ji Yun Lee, Jeong-Ok Lee, Soo-Mee Bang, Kwang-il Kim, Jee Hyun Kim
Received January 20, 2025  Accepted March 11, 2025  Published online March 12, 2025  
DOI: https://doi.org/10.4143/crt.2025.079    [Accepted]
AbstractAbstract PDF
Purpose
Older cancer patients face unique challenges due to age-related physiological changes, increasing their vulnerability to treatment-related toxicities. Geriatric assessment (GA) is a validated tool for optimizing care, yet there is no consensus on integrating geriatric interventions into oncology. This study evaluates the feasibility of a tailored onco-geriatric intervention model incorporating the KG-7 screening tool.
Materials and Methods
This prospective study included 30 patients aged ≥70 years with solid tumors undergoing adjuvant or palliative chemotherapy. Patients scoring ≤5 of KG-7 were eligible. Tailored interventions incorporating KG-7 included polypharmacy, functional status, mobility, nutrition, cognition, emotional well-being, insomnia, social support, and medical problem. KG-7, GA, and quality of life (QoL) were followed at 12 weeks.
Results
Participants (median age: 79.5 years) had colon (43.3%), pancreatic (23.3%), or gastric cancer (23.3%). At baseline, most patients showed independent ADL (100%)/IALD (90%). However, 93.3% had abnormal GA. Particularly, 86.7% were either malnourished or at risk of malnutrition. The most frequently identified intervention needs included polypharmacy (70.0%), nutritional support (60.0%), and emotional well-being (50.0%) with high adherence (100.0%, 88.9%, and 46.7%, respectively). At 12 weeks, KG-7 scores improved in 43.8% of patients, and 69.2% of GA domains were improved. QoL analysis revealed modest improvement in Global Health Status (mean difference 6.3, p=0.176). One-year survival rates were 92.3% and 79.4% for adjuvant and palliative groups, respectively.
Conclusion
The onco-geriatric intervention model incorporating KG-7 demonstrated high feasibility and potential to enhance clinical outcomes. Future studies should validate this approach in randomized trials to optimize care for older cancer patients.
  • 487 View
  • 13 Download
Close layer
Case Report
ALK Inhibition in a Patient with Inflammatory Myofibroblastic Tumor Harboring CARS1-ALK Fusion
Songji Choi, Miso Kim, Sheehyun Kim, Taekeun Park, Yoonjin Kwak, Jeong Mo Bae, Hongseok Yun, Jee Hyun Kim
Received December 10, 2024  Accepted December 14, 2024  Published online December 18, 2024  
DOI: https://doi.org/10.4143/crt.2024.1184    [Epub ahead of print]
AbstractAbstract PDFPubReaderePub
Inflammatory myofibroblastic tumor (IMT) is a rare entity, primarily affecting young individuals, often involving the abdomen, pelvis, or lung. Approximately 50% of IMTs harbor anaplastic lymphoma kinase (ALK) gene rearrangements, making ALK inhibitors a viable treatment. We report a case of a 40-year-old female with metastatic IMT harboring a CARS1-ALK fusion. Initial chemotherapy failed, but targeted therapy with alectinib through the KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II study led to significant tumor regression and ongoing, durable clinical improvement of 19 months. This case highlights the importance of precision medicine and raises the reappraisal of targeted agents outside of approved indications for rare cancers with actionable genomic alterations.

Citations

Citations to this article as recorded by  
  • Inflammatory myofibroblastic tumors of the colon in pediatrics: clinical presentation, management, and outcomes—A case report and systematic review of literature
    Ismael Elhalaby, Omar Koura, Rofyda Elhalaby, Wael Zeina, Mohamed Shareef, Essam Elhalaby
    International Journal of Colorectal Disease.2025;[Epub]     CrossRef
  • 506 View
  • 63 Download
  • 1 Crossref
Close layer
Original Articles
Hematologic malignancy
The Role of Direct Oral Anticoagulants in Managing Myeloproliferative Neoplasms Patients
Ji Yun Lee, Ju-Hyun Lee, Woochan Park, Jeongmin Seo, Minsu Kang, Eun Hee Jung, Sang-A Kim, Koung Jin Suh, Ji-Won Kim, Se Hyun Kim, Jeong-Ok Lee, Jin Won Kim, Yu Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang
Cancer Res Treat. 2025;57(2):612-620.   Published online September 20, 2024
DOI: https://doi.org/10.4143/crt.2024.738
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Thrombosis and bleeding significantly affect morbidity and mortality in myeloproliferative neoplasms (MPNs). The efficacy and safety of direct oral anticoagulants (DOACs) in MPN patients remain uncertain.
Materials and Methods
We conducted a large, retrospective, nationwide cohort study using the Korean Health Insurance Review and Assessment Service database from 2010 to 2021.
Results
Out of the 368 MPN patients included in the final analysis, 62.8% were treated with DOACs for atrial fibrillation (AF), and 37.2% for venous thromboembolism (VTE). The AF group was statistically older with higher CHA2DS2-VASc (congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke, transient ischemic attack, or thromboembolism, vascular disease, age 65-74 years, sex category [female]) scores compared to the VTE group. Antiplatelet agents were used in 51.1% of cases, and cytoreductive drugs in 79.3%, with hydroxyurea being the most common (64.9%). The median follow-up was 22.3 months, with 1-year cumulative incidence rates of thrombosis and bleeding at 11.1% and 3.7%, respectively. Multivariate analysis identified CHA2DS2-VASc scores ≥ 3 (hazard ratio [HR], 3.48), concomitant antiplatelet use (HR, 2.57), and cytoreduction (HR, 2.20) as significant thrombosis risk factors but found no significant predictors for major bleeding.
Conclusion
Despite the limitations of retrospective data, DOAC treatment in MPN patients seems effective and has an acceptable bleeding risk.

Citations

Citations to this article as recorded by  
  • Survey of Clinical Practice in Chronic Myeloproliferative Neoplasms in Croatia: A Study by the MPN Working Group Party of the Croatian Cooperative Group for Hematologic Diseases (KROHEM)
    Ivan Krecak, Marko Lucijanic, Rajko Kusec
    Journal of Clinical Medicine.2025; 14(5): 1524.     CrossRef
  • 1,354 View
  • 122 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Lung and Thoracic cancer
Association of TP53 Mutation Status and Sex with Clinical Outcome in Non–Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Retrospective Cohort Study
Songji Choi, Se Hyun Kim, Sejoon Lee, Jeongmin Seo, Minsu Kang, Eun Hee Jung, Sang-A Kim, Koung Jin Suh, Ji Yun Lee, Ji-Won Kim, Jin Won Kim, Jeong-Ok Lee, Yu Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Jong Seok Lee
Cancer Res Treat. 2025;57(1):70-82.   Published online August 7, 2024
DOI: https://doi.org/10.4143/crt.2024.046
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Some studies suggest that TP53 mutations are associated with the response to immune checkpoint inhibitors (ICI) in patients with non–small cell lung cancer (NSCLC) and also contribute to sex disparities in several cancers. Thus, we hypothesized that TP53 mutations might serve as sex-dependent genomic biomarkers of ICI treatment response in patients with NSCLC.
Materials and Methods
Clinical data of 100 patients with metastatic NSCLC treated with ICI monotherapy at Seoul National University Bundang Hospital (SNUBH) were retrospectively reviewed. Genomic and clinical datasets of The Cancer Genome Atlas and an ICI-treated lung cancer cohort (cBioPortal) were also analyzed.
Results
In SNUBH cohort, no statistically significant difference was observed in the median progression-free survival (PFS) according to TP53 mutation status (p=0.930); however, female patients with TP53 mutations (MT) had a significantly prolonged median PFS compared to wild-type (WT) (6.1 months in TP53 MT vs. 2.6 months in TP53 WT; p=0.021). Programmed death-ligand 1 (PD-L1) high (≥ 50%) expression was significantly enriched in female patients with TP53 MT (p=0.005). The analysis from publicly available dataset also revealed that females with NSCLC with TP53 MT showed significantly longer PFS than those with TP53 WT (p < 0.001). In The Cancer Genome Atlas analysis, expression of immune-related genes, and tumor mutation burden score in TP53 MT females were higher than in males without TP53 MT.
Conclusion
Female patients with NSCLC with TP53 mutations had high PD-L1 expression and showed favorable clinical outcomes following ICI therapy, suggesting a need for further research to explore the role of TP53 mutations for sex disparities in response to ICI therapy.

Citations

Citations to this article as recorded by  
  • Association Between TP53 Mutations and Platinum Resistance in a Cohort of High-Grade Serous Ovarian Cancer Patients: Novel Implications for Personalized Therapeutics
    Clelia Madeddu, Eleonora Lai, Manuela Neri, Elisabetta Sanna, Giulia Gramignano, Sonia Nemolato, Mario Scartozzi, Sabrina Giglio, Antonio Macciò
    International Journal of Molecular Sciences.2025; 26(5): 2232.     CrossRef
  • 1,661 View
  • 163 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Review Article
Precision Oncology Clinical Trials: A Systematic Review of Phase II Clinical Trials with Biomarker-Driven, Adaptive Design
Hyerim Ha, Hee Yeon Lee, Jee Hyun Kim, Do Yeun Kim, Ho Jung An, SeungJin Bae, Hye-sung Park, Jin Hyoung Kang
Cancer Res Treat. 2024;56(4):991-1013.   Published online May 7, 2024
DOI: https://doi.org/10.4143/crt.2024.128
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Novel clinical trial designs are conducted in the precision medicine era. This study aimed to evaluate biomarker-driven, adaptive phase II trials in precision oncology, focusing on infrastructure, efficacy, and safety. We systematically reviewed and analyzed the target studies. EMBASE and PubMed searches from 2015 to 2023 generated 29 eligible trials. Data extraction included infrastructure, biomarker screening methodologies, efficacy, and safety profiles. Government agencies, cancer hospitals, and academic societies with accumulated experiences led investigator-initiated precision oncology clinical trials (IIPOCTs), which later guided sponsor-initiated precision oncology clinical trials (SIPOCTs). Most SIPOCTs were international studies with basket design. IIPOCTs primarily used the central laboratory for biomarker screening, but SIPOCTs used both central and local laboratories. Most of the studies adapted next-generation sequencing and/or immunohistochemistry for biomarker screening. Fifteen studies included an independent central review committee for outcome investigation. Efficacy assessments predominantly featured objective response rate as the primary endpoint, with varying results. Nine eligible studies contributed to the United States Food and Drug Administration’s marketing authorization. Safety monitoring was rigorous, but reporting formats lacked uniformity. Health-related quality of life and patient-reported outcomes were described in some protocols but rarely reported. Our results reveal that precision oncology trials with adaptive design rapidly and efficiently evaluate anticancer drugs’ efficacy and safety, particularly in specified biomarker-driven cohorts. The evolution from IIPOCT to SIPOCT has facilitated fast regulatory approval, providing valuable insights into the precision oncology landscape.

Citations

Citations to this article as recorded by  
  • Co-Encapsulation of Multiple Antineoplastic Agents in Liposomes by Exploring Microfluidics
    Sajid Asghar, Radu Iliescu, Rares-Ionut Stiufiuc, Brindusa Dragoi
    International Journal of Molecular Sciences.2025; 26(8): 3820.     CrossRef
  • 3,166 View
  • 157 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Original Articles
Gastrointestinal cancer
Longitudinal Comparative Analysis of Circulating Tumor DNA and Matched Tumor Tissue DNA in Patients with Metastatic Colorectal Cancer Receiving Palliative First-Line Systemic Anti-Cancer Therapy
Seung-been Lee, Ji-Won Kim, Hong-Geun Kim, Sung-Hyun Hwang, Kui-Jin Kim, Ju Hyun Lee, Jeongmin Seo, Minsu Kang, Eun Hee Jung, Koung Jin Suh, Se Hyun Kim, Jin Won Kim, Yu Jung Kim, Jee Hyun Kim, Nak-Jung Kwon, Keun-Wook Lee
Cancer Res Treat. 2024;56(4):1171-1182.   Published online April 29, 2024
DOI: https://doi.org/10.4143/crt.2024.016
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to compare tumor tissue DNA (ttDNA) and circulating tumor DNA (ctDNA) to explore the clinical applicability of ctDNA and to better understand clonal evolution in patients with metastatic colorectal cancer undergoing palliative first-line systemic therapy.
Materials and Methods
We performed targeted sequencing analysis of 88 cancer-associated genes using germline DNA, ctDNA at baseline (baseline-ctDNA), and ctDNA at progressive disease (PD-ctDNA). The results were compared with ttDNA data.
Results
Among 208 consecutively enrolled patients, we selected 84 (41 males; median age, 59 years; range, 35 to 90 years) with all four sample types available. A total of 202 driver mutations were found in 34 genes. ttDNA exhibited the highest mutation frequency (n=232), followed by baseline-ctDNA (n=155) and PD-ctDNA (n=117). Sequencing ctDNA alongside ttDNA revealed additional mutations in 40 patients (47.6%). PD-ctDNA detected 13 novel mutations in 10 patients (11.9%) compared to ttDNA and baseline-ctDNA. Notably, seven mutations in five patients (6.0%) were missense or nonsense mutations in APC, TP53, SMAD4, and CDH1 genes. In baseline-ctDNA, higher maximal variant allele frequency (VAF) values (p=0.010) and higher VAF values of APC (p=0.012), TP53 (p=0.012), and KRAS (p=0.005) mutations were significantly associated with worse overall survival.
Conclusion
While ttDNA remains more sensitive than ctDNA, our ctDNA platform demonstrated validity and potential value when ttDNA was unavailable. Post-treatment analysis of PD-ctDNA unveiled new pathogenic mutations, signifying cancer’s clonal evolution. Additionally, baseline-ctDNA’s VAF values were prognostic after treatment.

Citations

Citations to this article as recorded by  
  • Precision-Guided Durable Response From Venetoclax With Decitabine in a Patient With a Metastatic Refractory IDH2 -Mutant Cholangiocarcinoma
    Eylül Özgü, Ünal Metin Tokat, Ashkan Adibi, Şevval Nur Bilgiç, Esranur Aydın, Onur Tutar, Mutlu Demiray
    JCO Precision Oncology.2025;[Epub]     CrossRef
  • Evolution of Neo-RAS-WT in Circulating Tumor DNA from First-Line to Subsequent Therapies in Metastatic Colorectal Cancer
    Marco Siringo, Michela De Meo, Irene Bottillo, Paola Grammatico, Enrico Cortesi, Chiara Nicolazzo, Paola Gazzaniga
    Cancers.2025; 17(7): 1070.     CrossRef
  • 2,705 View
  • 132 Download
  • 2 Web of Science
  • 2 Crossref
Close layer
Breast cancer
PD-L1 (SP142) Expression in Primary and Recurrent/Metastatic Triple-Negative Breast Cancers and Its Clinicopathological Significance
Eun Kyung Han, Ji Won Woo, Koung Jin Suh, Se Hyun Kim, Jee Hyun Kim, So Yeon Park
Cancer Res Treat. 2024;56(2):557-566.   Published online December 12, 2023
DOI: https://doi.org/10.4143/crt.2023.1025
AbstractAbstract PDFPubReaderePub
Purpose
The programmed death-ligand 1 (PD-L1) SP142 assay identifies patients with triple-negative breast cancer (TNBC) who are most likely to respond to the anti–PD-L1 agent atezolizumab. We aimed to compare PD-L1 (SP142) expression between primary and recurrent/metastatic TNBCs and elucidate the clinicopathological features associated with its expression.
Materials and Methods
Primary and recurrent/metastatic TNBCs tested with PD-L1 (SP142) were collected, and clinicopathological information of these cases was obtained through a review of slides and medical records.
Results
PD-L1 (SP142) positivity was observed in 50.9% (144/283) of primary tumors and 37.8% (31/82) of recurrent/metastatic TNBCs with a significant difference. Recurrent or metastatic sites were associated with PD-L1 positivity, with high PD-L1 positivity in the lung, breast, and soft tissues, and low positivity in the bone, skin, liver, and brain. When comparing PD-L1 expression between primary and matched recurrent/metastatic TNBCs using 55 paired samples, 20 cases (36.4%) showed discordance; 10 cases revealed positive conversion, and another 10 cases revealed negative conversion during metastatic progression. In primary TNBCs, PD-L1 expression was associated with a higher histologic grade, lower T category, pushing border, and higher tumor-infiltrating lymphocyte infiltration. In survival analyses, PD-L1 positivity, especially high positivity, was found to be associated with favorable prognosis of patients.
Conclusion
PD-L1 (SP142) expression was lower in recurrent/metastatic TNBCs, and substantial cases showed discordance in its expression between primary and recurrent/metastatic sites, suggesting that multiple sites may need to be tested for PD-L1 (SP142) when considering atezolizumab therapy. PD-L1 (SP142)–positive TNBCs seems to be associated with favorable clinical outcomes.

Citations

Citations to this article as recorded by  
  • Discrepancy of PD1/ PD-L1 status between primary and metastatic triple negative breast cancer in diagnostic biopsies
    Manar Moustafa, Basma Hamed Ibrahim
    Revista de Senología y Patología Mamaria.2025; 38(3): 100680.     CrossRef
  • Solamargine inhibits gastric cancer progression via inactivation of STAT3/PD‑L1 signaling
    Xiongxiang Liu, Lin Song, Wen Liu, Bin Liu, Lang Liu, Yao Su
    Molecular Medicine Reports.2024;[Epub]     CrossRef
  • Prevalence of Programmed Death-Ligand 1 Positivity Using SP142 in Patients With Advanced Stage Triple-Negative Breast Cancer in Malaysia: A Cross-Sectional Study
    Pathmanathan Rajadurai, Ning Yi Yap, Seow Fan Chiew, Reena Rahayu Md Zin, Suria Hayati Md Pauzi, Aniqah Shamimi Binti Jaafar, Azyani Yahaya, Lai Meng Looi
    Journal of Breast Cancer.2024; 27(6): 362.     CrossRef
  • 3,862 View
  • 191 Download
  • 3 Web of Science
  • 3 Crossref
Close layer
Special Article
Clinical Practice Recommendations for the Use of Next-Generation Sequencing in Patients with Solid Cancer: A Joint Report from KSMO and KSP
Miso Kim, Hyo Sup Shim, Sheehyun Kim, In Hee Lee, Jihun Kim, Shinkyo Yoon, Hyung-Don Kim, Inkeun Park, Jae Ho Jeong, Changhoon Yoo, Jaekyung Cheon, In-Ho Kim, Jieun Lee, Sook Hee Hong, Sehhoon Park, Hyun Ae Jung, Jin Won Kim, Han Jo Kim, Yongjun Cha, Sun Min Lim, Han Sang Kim, Choong-kun Lee, Jee Hung Kim, Sang Hoon Chun, Jina Yun, So Yeon Park, Hye Seung Lee, Yong Mee Cho, Soo Jeong Nam, Kiyong Na, Sun Och Yoon, Ahwon Lee, Kee-Taek Jang, Hongseok Yun, Sungyoung Lee, Jee Hyun Kim, Wan-Seop Kim
Cancer Res Treat. 2024;56(3):721-742.   Published online November 29, 2023
DOI: https://doi.org/10.4143/crt.2023.1043
AbstractAbstract PDFPubReaderePub
In recent years, next-generation sequencing (NGS)–based genetic testing has become crucial in cancer care. While its primary objective is to identify actionable genetic alterations to guide treatment decisions, its scope has broadened to encompass aiding in pathological diagnosis and exploring resistance mechanisms. With the ongoing expansion in NGS application and reliance, a compelling necessity arises for expert consensus on its application in solid cancers. To address this demand, the forthcoming recommendations not only provide pragmatic guidance for the clinical use of NGS but also systematically classify actionable genes based on specific cancer types. Additionally, these recommendations will incorporate expert perspectives on crucial biomarkers, ensuring informed decisions regarding circulating tumor DNA panel testing.

Citations

Citations to this article as recorded by  
  • Real-World Data: Implementation and Outcomes of Next-Generation Sequencing in the MENA Region
    Rami Mahfouz, Reine Abou Zeidane, Tasnim Diab, Ali Tarhini, Eman Sbaity, Houry Kazarian, Yomna El Zibaoui, Nour Sabiha Naji, Mounir Barake, Hazem I. Assi
    Diagnostics.2025; 15(10): 1183.     CrossRef
  • Exploring PIXE Applications in Oncology: A Comprehensive Review
    G. J. Naga Raju
    International Journal of Advanced Research in Science, Communication and Technology.2025; : 261.     CrossRef
  • 6,328 View
  • 336 Download
  • 2 Crossref
Close layer
Original Article
General
Impact of Patient Sex on Adverse Events and Unscheduled Utilization of Medical Services in Cancer Patients Undergoing Adjuvant Chemotherapy: A Multicenter Retrospective Cohort Study
Songji Choi, Seyoung Seo, Ju Hyun Lee, Koung Jin Suh, Ji-Won Kim, Jin Won Kim, Se Hyun Kim, Yu Jung Kim, Keun-Wook Lee, Jwa Hoon Kim, Tae Won Kim, Yong Sang Hong, Sun Young Kim, Jeong Eun Kim, Sang-We Kim, Dae Ho Lee, Jae Cheol Lee, Chang-Min Choi, Shinkyo Yoon, Su-Jin Koh, Young Joo Min, Yongchel Ahn, Hwa Jung Kim, Jin Ho Baek, Sook Ryun Park, Jee Hyun Kim
Cancer Res Treat. 2024;56(2):404-413.   Published online November 7, 2023
DOI: https://doi.org/10.4143/crt.2023.784
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The female sex is reported to have a higher risk of adverse events (AEs) from cytotoxic chemotherapy. Few studies examined the sex differences in AEs and their impact on the use of medical services during adjuvant chemotherapy. This sub-study aimed to compare the incidence of any grade and grade ≥ 3 AEs, healthcare utilization, chemotherapy completion rate, and dose intensity according to sex.
Materials and Methods
This is a sub-study of a multicenter cohort conducted in Korea that evaluated the impact of healthcare reimbursement on AE evaluation in patients who received adjuvant chemotherapy between September 2013 and December 2016 at four hospitals in Korea.
Results
A total of 1,170 patients with colorectal, gastric, or non–small cell lung cancer were included in the study. Female patients were younger, had fewer comorbidities, and experienced less postoperative weight loss of > 10%. Females had significantly higher rates of any grade AEs including nausea, abdominal pain, stomatitis, vomiting, and neutropenia, and experienced more grade ≥ 3 neutropenia, nausea, and vomiting. The dose intensity of chemotherapy was significantly lower in females, and they also experienced more frequent dose reduction after the first cycle. Moreover, female patients receiving platinum-containing regimens had significantly higher rates of unscheduled outpatient visits.
Conclusion
Our study found that females experienced a higher incidence of multiple any-grade AEs and severe neutropenia, nausea, and vomiting, across various cancer types, leading to more frequent dose reductions. Physicians should be aware of sex differences in AEs for chemotherapy decisions.

Citations

Citations to this article as recorded by  
  • Cancer care for transgender and gender‐diverse people: Practical, literature‐driven recommendations from the Multinational Association of Supportive Care in Cancer
    Elizabeth J. Cathcart‐Rake, Alexandre Chan, Alvaro Menendez, Denise Markstrom, Carla Schnitzlein, Yee Won Chong, Don S. Dizon
    CA: A Cancer Journal for Clinicians.2025; 75(1): 68.     CrossRef
  • Characterisation of the effects of the chemotherapeutic agent paclitaxel on neuropathic pain-related behaviour, anxiodepressive behaviour, cognition, and the endocannabinoid system in male and female rats
    Chiara Di Marino, Álvaro Llorente-Berzal, Alba M. Diego, Ariadni Bella, Laura Boullon, Esther Berrocoso, Michelle Roche, David P. Finn
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • [Translated article] Toxicity of the FOLFOX-6 regimen, with or without 5-fluorouracil bolus, in metastatic colorectal cancer
    María Teresa Garrido Martínez, María Rodríguez Jorge, Ignacio García Giménez, María Isabel Guzmán Ramos, Salvador Grutzmancher Sáiz, Victoria Aviñó Tarazona
    Farmacia Hospitalaria.2025;[Epub]     CrossRef
  • The Influence of Tumor Burden Score and Lymph Node Metastasis on the Survival Benefit of Adjuvant Chemotherapy in Intrahepatic Cholangiocarcinoma
    Jun Kawashima, Yutaka Endo, Selamawit Woldesenbet, Mujtaba Khalil, Miho Akabane, François Cauchy, Feng Shen, Shishir Maithel, Irinel Popescu, Minoru Kitago, Matthew J. Weiss, Guillaume Martel, Carlo Pulitano, Luca Aldrighetti, George Poultsides, Andrea Ru
    Annals of Surgical Oncology.2025; 32(6): 4341.     CrossRef
  • Toxicidad del esquema FOLFOX-6, asociado o no a bolo de 5-fluorouracilo, en cáncer colorrectal metastásico
    María Teresa Garrido Martínez, María Rodríguez Jorge, Ignacio García Giménez, María Isabel Guzmán Ramos, Salvador Grutzmancher Sáiz, Victoria Aviñó Tarazona
    Farmacia Hospitalaria.2024;[Epub]     CrossRef
  • 3,794 View
  • 169 Download
  • 3 Web of Science
  • 5 Crossref
Close layer
Erratum
ERRATUM: Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group
Shinkyo Yoon, Miso Kim, Yong Sang Hong, Han Sang Kim, Seung Tae Kim, Jihun Kim, Hongseok Yun, Changhoon Yoo, Hee Kyung Ahn, Hyo Song Kim, In Hee Lee, In-Ho Kim, Inkeun Park, Jae Ho Jeong, Jaekyung Cheon, Jin Won Kim, Jina Yun, Sun Min Lim, Yongjun Cha, Se Jin Jang, Dae Young Zang, Tae Won Kim, Jin Hyoung Kang, Jee Hyun Kim
Cancer Res Treat. 2023;55(3):1061-1061.   Published online April 21, 2023
DOI: https://doi.org/10.4143/crt.2021.1115.E
Corrects: Cancer Res Treat 2022;54(1):1
PDFPubReaderePub

Citations

Citations to this article as recorded by  
  • Real-World Data: Implementation and Outcomes of Next-Generation Sequencing in the MENA Region
    Rami Mahfouz, Reine Abou Zeidane, Tasnim Diab, Ali Tarhini, Eman Sbaity, Houry Kazarian, Yomna El Zibaoui, Nour Sabiha Naji, Mounir Barake, Hazem I. Assi
    Diagnostics.2025; 15(10): 1183.     CrossRef
  • 3,038 View
  • 115 Download
  • 1 Crossref
Close layer
Original Articles
Breast cancer
A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03)
Dae-Won Lee, Bhumsuk Keam, Keun Seok Lee, Jin-Hee Ahn, Joohyuk Sohn, Jin Seok Ahn, Moon Hee Lee, Jee Hyun Kim, Kyung Eun Lee, Hyo Jung Kim, Si-Young Kim, Yeon Hee Park, Chan-Young Ock, Kyung-Hun Lee, Sae-Won Han, Sung-Bae Kim, Young Hyuck Im, Hyun Cheol Chung, Do-Youn Oh, Seock-Ah Im
Cancer Res Treat. 2023;55(2):523-530.   Published online November 8, 2022
DOI: https://doi.org/10.4143/crt.2022.1360
AbstractAbstract PDFPubReaderePub
Purpose
This single-arm phase II trial investigate the efficacy and safety of S-1 plus oxaliplatin (SOX) in patients with metastatic breast cancer.
Materials and Methods
Patients with metastatic breast cancer previously treated with anthracyclines and taxanes were enrolled. Patients received S-1 (40-60 mg depending on patient’s body surface area, twice a day, day 1-14) and oxaliplatin (130 mg/m2, day 1) in 3 weeks cycle until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumor 1.1. Secondary endpoints included time-to-progression (TTP), duration-of-response (DoR), overall survival (OS), and adverse events.
Results
A total of 87 patients were enrolled from 11 institutions in Korea. Hormone receptor was positive in 54 (62.1%) patients and six (6.9%) had human epidermal growth factor receptor 2–positive disease. Forty-eight patients (85.1%) had visceral metastasis and 74 (55.2%) had more than three sites of metastases. The ORR of SOX regimen was 38.5% (95% confidence interval [CI], 26.9 to 50.0) with a median TTP of 6.0 months (95% CI, 5.1 to 6.9). Median DoR and OS were 10.3 months (95% CI, 5.5 to 15.1) and 19.4 (95% CI, not estimated) months, respectively. Grade 3 or 4 neutropenia was reported in 28 patients (32.1%) and thrombocytopenia was observed in 23 patients (26.6%).
Conclusion
This phase II study showed that SOX regimen is a reasonable option in metastatic breast cancer previously treated with anthracyclines and taxanes.

Citations

Citations to this article as recorded by  
  • Unraveling the immune landscape and therapeutic biomarker PMEPA1 for oxaliplatin resistance in colorectal cancer: A comprehensive approach
    Zhengguang Zhang, Tianming Lu, Zhe Zhang, Zixian Liu, Ruoning Qian, Ruogu Qi, Fuqiong Zhou, Min Li
    Biochemical Pharmacology.2024; 222: 116117.     CrossRef
  • Efficacy and safety of utidelone plus capecitabine in advanced first-line therapy for metastatic breast cancer: A multicenter real-world study
    Pingping Bi, Xi Wang, Rui Liu, Xiuqin Li, Shanrong Wei, Jiawen Zhao, Xin Tan, Fan Zhang, Qing Mao, Ying Zhang, Baoyan Tang, Xueqiong Xun, Rong Guo, Kai Zheng, Shaoqiang Zhou, Shicong Tang
    Surgery Open Science.2023; 16: 171.     CrossRef
  • 5,086 View
  • 173 Download
  • 2 Web of Science
  • 2 Crossref
Close layer
The Pattern of Care for Brain Metastasis from Breast Cancer over the Past 10 Years in Korea: A Multicenter Retrospective Study (KROG 16-12)
Jae Sik Kim, Kyubo Kim, Wonguen Jung, Kyung Hwan Shin, Seock-Ah Im, Hee-Jun Kim, Yong Bae Kim, Jee Suk Chang, Jee Hyun Kim, Doo Ho Choi, Yeon Hee Park, Dae Yong Kim, Tae Hyun Kim, Byung Ock Choi, Sea-Won Lee, Suzy Kim, Jeanny Kwon, Ki Mun Kang, Woong-Ki Chung, Kyung Su Kim, Ji Ho Nam, Won Sup Yoon, Jin Hee Kim, Jihye Cha, Yoon Kyeong Oh, In Ah Kim
Cancer Res Treat. 2022;54(4):1121-1129.   Published online December 31, 2021
DOI: https://doi.org/10.4143/crt.2021.1083
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We aimed to investigate manifestations and patterns of care for patients with brain metastasis (BM) from breast cancer (BC) and compared their overall survival (OS) from 2005 through 2014 in Korea.
Materials and Methods
We retrospectively reviewed 600 BC patients with BM diagnosed between 2005 and 2014. The median follow-up duration was 12.5 months. We categorized the patients into three groups according to the year when BM was initially diagnosed (group I [2005-2008], 98 patients; group II [2009-2011], 200 patients; and group III [2012-2014], 302 patients).
Results
Over time, the median age at BM diagnosis increased by 2.2 years (group I, 49.0 years; group II, 48.3 years; and group III, 51.2 years; p=0.008). The percentage of patients with extracranial metastasis was 73.5%, 83.5%, and 86.4% for group I, II, and III, respectively (p=0.011). The time interval between BC and BM was prolonged in patients with stage III primary BC (median, 2.4 to 3 years; p=0.029). As an initial brain-directed treatment, whole-brain radiotherapy alone decreased from 80.0% in 2005 to 41.1% in 2014. Meanwhile, stereotactic radiosurgery or fractionated stereotactic radiotherapy alone increased from 13.3% to 34.7% during the same period (p=0.005). The median OS for group I, II, and III was 15.6, 17.9, and 15.0 months, respectively, with no statistical significance.
Conclusion
The manifestations of BM from BC and the pattern of care have changed from 2005 to 2014 in Korea. However, the OS has remained relatively unchanged over the 10 years.

Citations

Citations to this article as recorded by  
  • Comparison of initial and sequential salvage brain-directed treatment in patients with 1–4 vs. 5–10 brain metastases from breast cancer (KROG 16–12)
    Jae Sik Kim, Kyubo Kim, Wonguen Jung, Kyung Hwan Shin, Seock-Ah Im, Hee-Jun Kim, Yong Bae Kim, Jee Suk Chang, Jee Hyun Kim, Doo Ho Choi, Yeon Hee Park, Dae Yong Kim, Tae Hyun Kim, Byung Ock Choi, Sea-Won Lee, Suzy Kim, Jeanny Kwon, Ki Mun Kang, Woong-Ki C
    Breast Cancer Research and Treatment.2023; 200(1): 37.     CrossRef
  • 6,761 View
  • 188 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Special Article
Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group
Shinkyo Yoon, Miso Kim, Yong Sang Hong, Han Sang Kim, Seung Tae Kim, Jihun Kim, Hongseok Yun, Changhoon Yoo, Hee Kyung Ahn, Hyo Song Kim, In Hee Lee, In-Ho Kim, Inkeun Park, Jae Ho Jeong, Jaekyung Cheon, Jin Won Kim, Jina Yun, Sun Min Lim, Yongjun Cha, Se Jin Jang, Dae Young Zang, Tae Won Kim, Jin Hyoung Kang, Jee Hyun Kim
Cancer Res Treat. 2022;54(1):1-9.   Published online December 13, 2021
DOI: https://doi.org/10.4143/crt.2021.1115
Correction in: Cancer Res Treat 2023;55(3):1061
AbstractAbstract PDFPubReaderePub
Next-generation sequencing (NGS) is becoming essential in the fields of precision oncology. With implementation of NGS in daily clinic, the needs for continued education, facilitated interpretation of NGS results and optimal treatment delivery based on NGS results have been addressed. Molecular tumor board (MTB) is multidisciplinary approach to keep pace with the growing knowledge of complex molecular alterations in patients with advanced solid cancer. Although guidelines for NGS use and MTB have been developed in western countries, there is limitation for reflection of Korea’s public health environment and daily clinical practice. These recommendations provide a critical guidance from NGS panel testing to final treatment decision based on MTB discussion.

Citations

Citations to this article as recorded by  
  • Clinical implementation of next-generation sequencing testing and genomically-matched therapy: a real-world data in a tertiary hospital
    Jin Won Kim, Hee Young Na, Sejoon Lee, Ji-Won Kim, Koung Jin Suh, Se Hyun Kim, Yu Jung Kim, Keun-Wook Lee, Jong Seok Lee, Jaihwan Kim, Jin-Hyeok Hwang, Kihwan Hwang, Chae-Yong Kim, Yong Beom Kim, Soomin Ahn, Kyu Sang Lee, Hyojin Kim, Hye Seung Lee, So Yeo
    Scientific Reports.2025;[Epub]     CrossRef
  • Expert Consensus on Molecular Tumor Boards in Taiwan: Joint Position Paper by the Taiwan Oncology Society and the Taiwan Society of Pathology
    Ming-Huang Chen, Wan-Shan Li, Bin-Chi Liao, Chiao-En Wu, Chien-Feng Li, Chia-Hsun Hsieh, Feng-Che Kuan, Huey-En Tzeng, Jen-Fan Hang, Nai-Jung Chiang, Tse-Ching Chen, Tom Wei-Wu Chen, John Wen-Cheng Chang, Yao-Yu Hsieh, Yen-Lin Chen, Yi-Chen Yeh, Yi-Hsin L
    Journal of Cancer Research and Practice.2024;[Epub]     CrossRef
  • Pragmatic nationwide master observational trial based on genomic alterations in advanced solid tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II
    Sun Young Kim, Jee Hyun Kim, Tae-Yong Kim, Sook Ryun Park, Shinkyo Yoon, Soohyeon Lee, Se-Hoon Lee, Tae Min Kim, Sae-Won Han, Hye Ryun Kim, Hongseok Yun, Sejoon Lee, Jihun Kim, Yoon-La Choi, Kui Son Choi, Heejung Chae, Hyewon Ryu, Gyeong-Won Lee, Dae Youn
    BMC Cancer.2024;[Epub]     CrossRef
  • Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort
    I. Vanni, L. Pastorino, V. Andreotti, D. Comandini, G. Fornarini, M. Grassi, A. Puccini, E. T. Tanda, A. Pastorino, V. Martelli, L. Mastracci, F. Grillo, F. Cabiddu, A. Guadagno, S. Coco, E. Allavena, F. Barbero, W. Bruno, B. Dalmasso, S. E. Bellomo, C. M
    Journal of Translational Medicine.2024;[Epub]     CrossRef
  • Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSP
    Miso Kim, Hyo Sup Shim, Sheehyun Kim, In Hee Lee, Jihun Kim, Shinkyo Yoon, Hyung-Don Kim, Inkeun Park, Jae Ho Jeong, Changhoon Yoo, Jaekyung Cheon, In-Ho Kim, Jieun Lee, Sook Hee Hong, Sehhoon Park, Hyun Ae Jung, Jin Won Kim, Han Jo Kim, Yongjun Cha, Sun
    Journal of Pathology and Translational Medicine.2024; 58(4): 147.     CrossRef
  • Clinical Practice Recommendations for the Use of Next-Generation Sequencing in Patients with Solid Cancer: A Joint Report from KSMO and KSP
    Miso Kim, Hyo Sup Shim, Sheehyun Kim, In Hee Lee, Jihun Kim, Shinkyo Yoon, Hyung-Don Kim, Inkeun Park, Jae Ho Jeong, Changhoon Yoo, Jaekyung Cheon, In-Ho Kim, Jieun Lee, Sook Hee Hong, Sehhoon Park, Hyun Ae Jung, Jin Won Kim, Han Jo Kim, Yongjun Cha, Sun
    Cancer Research and Treatment.2024; 56(3): 721.     CrossRef
  • Nationwide precision oncology pilot study: KOrean Precision Medicine Networking Group Study of MOlecular profiling-guided therapy based on genomic alterations in advanced solid tumors (KOSMOS) KCSG AL-20-05
    T.-Y. Kim, S.Y. Kim, J.H. Kim, H.A. Jung, Y.J. Choi, I.G. Hwang, Y. Cha, G.-W. Lee, Y.-G. Lee, T.M. Kim, S.-H. Lee, S. Lee, H. Yun, Y.L. Choi, S. Yoon, S.W. Han, T.-Y. Kim, T.W. Kim, D.Y. Zang, J.H. Kang
    ESMO Open.2024; 9(10): 103709.     CrossRef
  • Utilizing Plasma Circulating Tumor DNA Sequencing for Precision Medicine in the Management of Solid Cancers
    Yongjun Cha, Sheehyun Kim, Sae-Won Han
    Cancer Research and Treatment.2023; 55(2): 367.     CrossRef
  • Mutational evolution after chemotherapy‐progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis
    Sheehyun Kim, Yongjun Cha, Yoojoo Lim, Hanseong Roh, Jun‐Kyu Kang, Kyung‐Hun Lee, Min Jung Kim, Ji Won Park, Seung‐Bum Ryoo, Hwang‐Phill Kim, Seung‐Yong Jeong, Kyu Joo Park, Sae‐Won Han, Tae‐You Kim
    International Journal of Cancer.2023; 153(3): 571.     CrossRef
  • Establishing molecular pathology curriculum for pathology trainees and continued medical education: a collaborative work from the Molecular Pathology Study Group of the Korean Society of Pathologists
    Jiwon Koh, Ha Young Park, Jeong Mo Bae, Jun Kang, Uiju Cho, Seung Eun Lee, Haeyoun Kang, Min Eui Hong, Jae Kyung Won, Youn-La Choi, Wan-Seop Kim, Ahwon Lee
    Journal of Pathology and Translational Medicine.2023; 57(5): 265.     CrossRef
  • Implementation of Precision Oncology in the National Healthcare System: A Statement Proposal Endorsed by Italian Scientific Societies
    Gianpiero Fasola, Maria C. Barducci, Valeria D. Tozzi, Luigi Cavanna, Saverio Cinieri, Francesco Perrone, Carmine Pinto, Antonio Russo, Anna Sapino, Francesco Grossi, Giuseppe Aprile
    JCO Precision Oncology.2023;[Epub]     CrossRef
  • Development of two 410-cancer-gene panel tests for solid tumors and liquid biopsy based on genome data of 5,143 Japanese cancer patients
    Yuji SHIMODA, Takeshi NAGASHIMA, Kenichi URAKAMI, Fukumi KAMADA, Sou NAKATANI, Maki MIZUGUCHI, Masakuni SERIZAWA, Keiichi HATAKEYAMA, Keiichi OHSHIMA, Tohru MOCHIZUKI, Sumiko OHNAMI, Shumpei OHNAMI, Takeshi KAWAKAMI, Kentaro YAMAZAKI, Haruyasu MURAKAMI, H
    Biomedical Research.2022; 43(4): 115.     CrossRef
  • Clinical Implication of Molecular Tumor Board
    Soohyeon Lee
    The Korean Journal of Medicine.2022; 97(5): 319.     CrossRef
  • Somatic Mutations of TP53 Identified by Targeted Next-Generation Sequencing Are Poor Prognostic Factors for Primary Operable Breast Cancer: A Single-Center Study
    Jung Ho Park, Mi Jung Kwon, Jinwon Seo, Ho Young Kim, Soo Kee Min, Lee Su Kim
    Journal of Breast Cancer.2022; 25(5): 379.     CrossRef
  • 10,870 View
  • 546 Download
  • 14 Web of Science
  • 14 Crossref
Close layer
Original Articles
Breast cancer
Effect of Estrogen Receptor Expression Level and Hormonal Therapy on Prognosis of Early Breast Cancer
Kyung-Hwak Yoon, Yeshong Park, Eunyoung Kang, Eun-Kyu Kim, Jee Hyun Kim, Se Hyun Kim, Koung Jin Suh, Sun Mi Kim, Mijung Jang, Bo La Yun, So Yeon Park, Hee-Chul Shin
Cancer Res Treat. 2022;54(4):1081-1090.   Published online November 17, 2021
DOI: https://doi.org/10.4143/crt.2021.890
AbstractAbstract PDFPubReaderePub
Purpose
Estrogen receptor (ER) expression in breast cancer plays an essential role in carcinogenesis and disease progression. Recently, tumors with low level (1%-10%) of ER expression have been separately defined as ER low positive (ERlow). It is suggested that ERlow tumors might be morphologically and behaviorally different from tumors with high ER expression (ERhigh).
Materials and Methods
Retrospective analysis of a prospective cohort database was performed. Patients who underwent curative surgery for early breast cancer and had available medical records were included for analysis. Difference in clinicopathological characteristics, endocrine responsiveness and five-year recurrence-free survival was evaluated between different ER subgroups (ERhigh, ERlow, and ER-negative [ER–]).
Results
A total of 2,162 breast cancer patients were included in the analysis, Tis and T1 stage. Among them, 1,654 (76.5%) were ERhigh, 54 (2.5%) were ERlow, and 454 (21.0%) were ER- patients. ERlow cases were associated with smaller size, higher histologic grade, positive human epidermal growth factor receptor 2, negative progesterone receptor, and higher Ki-67 expression. Recurrence rate was highest in ER– tumors and was inversely proportional to ER expression. Recurrence-free survival was not affected by hormonal therapy in the ERlow group (p=0.418).
Conclusion
ERlow breast cancer showed distinct clinicopathological features. ERlow tumors seemed to have higher recurrence rates compared to ERhigh tumors, and they showed no significant benefit from hormonal therapy. Future large scale prospective studies are necessary to validate the treatment options for ERlow breast cancer.

Citations

Citations to this article as recorded by  
  • CYP2D6 Genotyping for Optimization of Tamoxifen Therapy in Indonesian Women with ER+ Breast Cancer
    Baitha Palanggatan Maggadani, Kathleen Irena Junusmin, Fatma Aldila, Jessica Audrienna, Bijak Rabbani, Yusuf Maulana, Sabrina Gabriel Tanu, Gabriella Gabriella, Margareta Amelia, Faustina Audrey Agatha, Marco Wijaya, Stevany Tiurma Sormin, Caroline Mahend
    Journal of Personalized Medicine.2025; 15(3): 93.     CrossRef
  • Prognosis, clinicopathological characteristics, and treatment patterns of patients with ER-intermediate-positive breast cancer undergoing long-term follow-up
    N. Matsumoto, Y. Wanifuchi-Endo, T. Fujita, T. Asano, M. Terada, K. Nozawa, M. Mori, A. Isogai, Y. Niwa, H. Kato, M. Komura, T. Toyama
    ESMO Open.2025; 10(4): 104508.     CrossRef
  • ER-positive and BRCA2-mutated breast cancer: a literature review
    Pu-Chun Li, Yi-Fan Zhu, Wen-Ming Cao, Bei Li
    European Journal of Medical Research.2024;[Epub]     CrossRef
  • Affibody PET Imaging of HER2-Expressing Cancers as a Key to Guide HER2-Targeted Therapy
    Nina Eissler, Renske Altena, Ali Alhuseinalkhudhur, Olga Bragina, Joachim Feldwisch, Guido Wuerth, Annika Loftenius, Nikolai Brun, Rimma Axelsson, Vladimir Tolmachev, Jens Sörensen, Fredrik Y. Frejd
    Biomedicines.2024; 12(5): 1088.     CrossRef
  • Distinct ER and PR expression patterns significantly affect the clinical outcomes of early HER2-positive breast cancer: A real-world analysis of 871 patients treated with neoadjuvant therapy
    Haizhu Chen, Xiujuan Gui, Ziwei Zhou, Fengxi Su, Chang Gong, Shunrong Li, Wei Wu, Nanyan Rao, Qiang Liu, Herui Yao
    The Breast.2024; 75: 103733.     CrossRef
  • HR-positive/HER2-negative breast cancer arising in patients with or without BRCA2 mutation: different biological phenotype and similar prognosis
    Pu-Chun Li, Yi-Fan Zhu, Jia-Ni Pan, Qiao-Yan Zhu, Yu-Yang Liao, Xiao-Wen Ding, Lin-Feng Zheng, Wen-Ming Cao
    Therapeutic Advances in Medical Oncology.2024;[Epub]     CrossRef
  • Is the percentage of hormone receptor positivity in HR+ HER2-metastatic breast cancer patients receiving CDK 4/6 inhibitor with endocrine therapy predictive and prognostic?
    Merve Keskinkilic, Huseyin Salih Semiz, Tugba Yavuzsen, Ilhan Oztop
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Rat Models of Hormone Receptor-Positive Breast Cancer
    Raquel Nicotra, Catrin Lutz, Hendrik A. Messal, Jos Jonkers
    Journal of Mammary Gland Biology and Neoplasia.2024;[Epub]     CrossRef
  • Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer
    Davide Massa, Claudio Vernieri, Lorenzo Nicolè, Carmen Criscitiello, Florence Boissière-Michot, Séverine Guiu, Angélique Bobrie, Gaia Griguolo, Federica Miglietta, Andrea Vingiani, Riccardo Lobefaro, Beatrice Taurelli Salimbeni, Claudia Pinato, Francesca
    JNCI: Journal of the National Cancer Institute.2024; 116(12): 1914.     CrossRef
  • Trends in the incidence and survival of women with hormone receptor-positive breast cancer from 1990 to 2019: a large population-based analysis
    Hongbo Huang, Tingting Wei, Aijie Zhang, Heng Zhang, Lingquan Kong, Yunhai Li, Fan Li
    Scientific Reports.2024;[Epub]     CrossRef
  • The “lows”: Update on ER-low and HER2-low breast cancer
    Nicola Fusco, Giuseppe Viale
    The Breast.2024; 78: 103831.     CrossRef
  • Estrogenized HSA induced high-affinity autoantibodies in breast cancer - Novel biomarker for early detection
    Subuhi Sherwani, Mohd Wajid Ali Khan, Wahid Ali Khan, Saravanan Rajendrasozhan, Khalid Al-Motair, Hamda Khan, Saheem Ahmad
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Transcription factors and hormone receptors: Sex‑specific targets for cancer therapy (Review)
    Juyeon Kim, Hyobin Bang, Cheyun Seong, Eun-Sook Kim, Sun Kim
    Oncology Letters.2024;[Epub]     CrossRef
  • Impact of prolactin treatment on enhancing the cellular responses of MCF7 breast cancer cells to tamoxifen treatment
    Anwar Shams
    Discover Oncology.2024;[Epub]     CrossRef
  • Missing link between tissue specific expressing pattern of ERβ and the clinical manifestations in LGBLEL
    Xujuan Zhang, Pengxiang Zhao, Mingshen Ma, Hao Wu, Rui Liu, Ziyi Liu, Zisong Cai, Mengyu Liu, Fei Xie, Xuemei Ma
    Frontiers in Medicine.2023;[Epub]     CrossRef
  • Assessment of breast cytoarchitecture and its associated axillary lymph node status under normal and pathological conditions in Egyptian women
    Omnia Mansour, Amani Kazem, Abeer El Wakil
    Tissue and Cell.2023; 85: 102244.     CrossRef
  • Estrogen-Receptor-Low-Positive Breast Cancer: Pathological and Clinical Perspectives
    Christina Panagiotis Malainou, Nikolina Stachika, Aikaterini Konstantina Damianou, Aristotelis Anastopoulos, Ioanna Ploumaki, Efthymios Triantafyllou, Konstantinos Drougkas, Georgia Gomatou, Elias Kotteas
    Current Oncology.2023; 30(11): 9734.     CrossRef
  • 7,914 View
  • 234 Download
  • 19 Web of Science
  • 17 Crossref
Close layer
A Real-world Efficacy of Nab-paclitaxel Monotherapy in Metastatic Breast Cancer
Jung Sun Kim, Koung Jin Suh, Dae-Won Lee, Go-un Woo, Miso Kim, Se Hyun Kim, Han Suk Ryu, Kyung-Hun Lee, Tae-Yong Kim, Sae-Won Han, So Yeon Park, In Ae Park, Jee Hyun Kim, Seock-Ah Im
Cancer Res Treat. 2022;54(2):488-496.   Published online August 13, 2021
DOI: https://doi.org/10.4143/crt.2021.394
AbstractAbstract PDFPubReaderePub
Purpose
We aimed to assess the real-world efficacy of nab-paclitaxel in metastatic breast cancer patients.
Materials and Methods
This is a retrospective study performed in two tertiary referral hospitals in Korea. Patients with metastatic breast cancer treated with nab-paclitaxel (Abraxane®) between March 2016 and March 2020 were enrolled.
Results
A total of 102 patients with metastatic breast cancer were included. Patients were heavily pre-treated with a median of four prior lines of chemotherapy (5 lines when including endocrine therapy in hormone-receptor-positive patients), and 66 patients (64.7%) were exposed to taxanes in the metastatic setting. According to St. Gallen molecular subtypes, 36 patients (35.3%) were luminal A, 28 (27.5%) were luminal B, 18 (17.7%) were human epidermal growth factor receptor 2–positive and 20 (19.6%) had triple-negative disease. Fifty patients (49.0%) were treated with a 3-weekly regimen (260 mg/m2 on day 1 every 3 weeks), and 52 (51.0%) were treated with a weekly regimen (100 mg/m2 every week). Objective response rate was 22.9%. After a median follow-up of 22.0 months, median progression-free survival (PFS) was 4.0 months (95% confidence interval [CI], 2.6 to 4.8) and median overall survival was 8.7 months (95% CI, 7.5 to 11.2). Patients treated with weekly regimen had longer PFS compared to 3-weekly regimen (5.5 vs. 2.3 months, p < 0.001). Multivariate analysis revealed the treatment regimen as an independent prognostic factor for PFS. There was no grade 3 or 4 hypersensitivity reaction.
Conclusion
This real-world data shows that nab-paclitaxel is a reasonable treatment option in heavily pre-treated and/or taxane-exposed metastatic breast cancer patients.

Citations

Citations to this article as recorded by  
  • Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
    P. Meyer-Wilmes, J. Huober, M. Untch, J.-U. Blohmer, W. Janni, C. Denkert, P. Klare, T. Link, K. Rhiem, C. Bayer, M. Reinisch, V. Bjelic-Radisic, D.M. Zahm, C. Hanusch, C. Solbach, G. Heinrich, A.D. Hartkopf, A. Schneeweiss, P. Fasching, N. Filmann, V. Ne
    ESMO Open.2024; 9(5): 103009.     CrossRef
  • Real-world study on the effect of nab-paclitaxel treatment on clinical outcomes and laboratory parameters in patients across metastatic tumor sites
    Vikas Talreja, Sangeeta Khetwani, Ethirajan Nanadagopal, Nilesh Eknath Borkar, Kunal Khobragade
    International Journal of Molecular and Immuno Oncology.2024; 9: 46.     CrossRef
  • Safety and efficacy of generic nab-paclitaxel-based therapy in Chinese patients with malignant tumors in a real-world setting: a multicenter prospective observational study
    Fei He, Yancai Sun, Wenzhou Zhang, Qiongshi Wu, Donghang Xu, Zaixian Bai, Zhiying Hao, Weiyi Feng, Kanghuai Zhang, Jiang Liu, Mei Dong, Guangxuan Liu, Guohui Li
    Discover Oncology.2024;[Epub]     CrossRef
  • Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: a retrospective study
    Zhichao Tian, Shuping Dong, Yang Yang, Shilei Gao, Yonghao Yang, Jinpo Yang, Peng Zhang, Xin Wang, Weitao Yao
    BMC Cancer.2022;[Epub]     CrossRef
  • Paclitaxel

    Reactions Weekly.2022; 1926(1): 383.     CrossRef
  • Natural Taxanes: From Plant Composition to Human Pharmacology and Toxicity
    Ľuboš Nižnanský, Denisa Osinová, Roman Kuruc, Alexandra Hengerics Szabó, Andrea Szórádová, Marián Masár, Žofia Nižnanská
    International Journal of Molecular Sciences.2022; 23(24): 15619.     CrossRef
  • A Novel Microcrystalline BAY-876 Formulation Achieves Long-Acting Antitumor Activity Against Aerobic Glycolysis and Proliferation of Hepatocellular Carcinoma
    Hua Yang, Mu-Zi-he Zhang, Hui-wei Sun, Yan-tao Chai, Xiaojuan Li, Qiyu Jiang, Jun Hou
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • 8,066 View
  • 230 Download
  • 5 Web of Science
  • 7 Crossref
Close layer
Palliative medicine
A Prognostic Model to Facilitate Palliative Care Referral in Oncology Outpatients
Yu Jung Kim, Yusuke Hiratsuka, Sang-Yeon Suh, Beodeul Kang, Si Won Lee, Hong-Yup Ahn, Koung Jin Suh, Ji-Won Kim, Se Hyun Kim, Jin Won Kim, Keun-Wook Lee, Jee Hyun Kim, Jong Seok Lee
Cancer Res Treat. 2022;54(2):621-629.   Published online July 12, 2021
DOI: https://doi.org/10.4143/crt.2021.483
AbstractAbstract PDFPubReaderePub
Purpose
We aimed to develop a prognostic model to assist palliative care referral at least 3 months before death in advanced cancer patients treated at an outpatient medical oncology clinic.
Materials and Methods
In this prospective cohort study, a total of 200 patients were enrolled at a tertiary cancer center in South Korea. The major eligibility criterion was an expected survival of less than a year as estimated by their oncologists. We analyzed the influences of known prognostic factors along with chemotherapy status, mid-arm circumference, and triceps skinfold thickness on survival time.
Results
The mean age of the patients was 64.5 years, 36% were female, and the median survival time was 7.6 months. In the multivariate analysis, we found 6 significant factors related to poor survival: a poor Eastern Cooperative Oncology Group (ECOG) performance status (≥2), not undergoing chemotherapy, anorexia, a low lymphocyte level (<12%), a high lactate dehydrogenase (LDH) level (≥300 IU/L), and a low mid-arm circumference (<23 cm). We developed a prognostic model (score, 0-8.0) to predict 3-month survival based on the multivariate analysis. Patients who scored ≥4.0 points had a short survival of less than 3 months (p<0.001). The discriminating ability of the prognostic model using the area under the receiver operating characteristic curve (AUC) was 0.88.
Conclusion
The prognostic model using ECOG performance status, chemotherapy status, anorexia, lymphocytes, LDH, and mid-arm circumference can predict 3-month survival in medical oncology outpatients. It can alert oncologists to refer patients to palliative care specialists before it is too late.

Citations

Citations to this article as recorded by  
  • Clinicians’ Prediction of Survival Is Most Useful for Palliative Care Referral
    Eun Hee Jung, Yusuke Hiratsuka, Sang-Yeon Suh, Seok-Joon Yoon, Beodeul Kang, Si Won Lee, Koung Jin Suh, Ji-Won Kim, Se Hyun Kim, Jin Won Kim, Keun-Wook Lee, Yu Jung Kim
    Palliative Medicine Reports.2024; 5(1): 365.     CrossRef
  • 8,413 View
  • 175 Download
  • 3 Web of Science
  • 1 Crossref
Close layer
Gastrointestinal Cancer
Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer
Kyung-Hun Lee, Eui Kyu Chie, Seock-Ah Im, Jee Hyun Kim, Jihyun Kwon, Sae-Won Han, Do-Youn Oh, Jin-Young Jang, Jae-Sung Kim, Tae-You Kim, Yung-Jue Bang, Sun Whe Kim, Sung W. Ha
Cancer Res Treat. 2021;53(4):1096-1103.   Published online December 30, 2020
DOI: https://doi.org/10.4143/crt.2020.928
AbstractAbstract PDFPubReaderePub
Purpose
Despite curative resection, the 5-year survival for patients with resectable pancreatic cancer is less than 20%. Recurrence occurs both locally and at distant sites and effective multimodality adjuvant treatment is needed.
Materials and Methods
Patients with curatively resected stage IB-IIB pancreatic adenocarcinoma were eligible. Treatment consisted of chemotherapy with gemcitabine 1,000 mg/m2 on days 1 and 8 and cisplatin 60 mg/m2 on day 1 every 3 weeks for two cycles, followed by chemoradiotherapy (50.4 Gy/28 fx) with weekly gemcitabine (300 mg/m2/wk), and then gemcitabine 1,000 mg/m2 on days 1 and 8 every 3 weeks for four cycles. The primary endpoint was 1-year disease-free survival rate. The secondary endpoints were disease-free survival, overall survival, and safety.
Results
Seventy-four patients were enrolled. One-year disease-free survival rate was 57.9%. Median disease-free and overall survival were 15.0 months (95% confidence interval [CI], 11.6 to 18.4) and 33.0 months (95% CI, 21.8 to 44.2), respectively. At the median follow-up of 32 months, 57 patients (77.0%) had recurrence including 11 patients whose recurrence was during the adjuvant treatment. Most of the recurrences were systemic (52 patients). Stage at the time of diagnosis (70.0% in IIA, 51.2% in IIB, p=0.006) were significantly related with 1-year disease-free survival rate. Toxicities were generally tolerable, with 53 events of grade 3 or 4 hematologic toxicity and four patients with febrile neutropenia.
Conclusion
Adjuvant gemcitabine and cisplatin chemotherapy followed by chemoradiotherapy with gemcitabine and maintenance gemcitabine showed efficacy and good tolerability in curatively resected pancreatic cancer.

Citations

Citations to this article as recorded by  
  • NUDT21 interacts with NDUFS2 to activate the PI3K/AKT pathway and promotes pancreatic cancer pathogenesis
    Xiao-Dong Huang, Yong-Wei Chen, Lv Tian, Li Du, Xiao-Chen Cheng, Yu-Xin Lu, Dong-Dong Lin, Feng-Jun Xiao
    Journal of Cancer Research and Clinical Oncology.2024;[Epub]     CrossRef
  • Efficacy of Cisplatin-Containing Chemotherapy Regimens in Patients of Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis
    Obaid Ur Rehman, Eeshal Fatima, Zain Ali Nadeem, Arish Azeem, Jatin Motwani, Habiba Imran, Hadia Mehboob, Alishba Khan, Omer Usman
    Journal of Gastrointestinal Cancer.2024; 55(2): 559.     CrossRef
  • OTUB1/NDUFS2 axis promotes pancreatic tumorigenesis through protecting against mitochondrial cell death
    Xiao-Dong Huang, Li Du, Xiao-Chen Cheng, Yu-Xin Lu, Qiao-Wei Liu, Yi-Wu Wang, Ya-Jin Liao, Dong-Dong Lin, Feng-Jun Xiao
    Cell Death Discovery.2024;[Epub]     CrossRef
  • Impact of obesity on pathological complete remission in early stage breast cancer patients after neoadjuvant chemotherapy: a retrospective study from a German University breast center
    Johannes Felix Englisch, Alexander Englisch, Dominik Dannehl, Kenneth Eissler, Christian Martin Tegeler, Sabine Matovina, Léa Louise Volmer, Diethelm Wallwiener, Sara Y. Brucker, Andreas Hartkopf, Tobias Engler
    Archives of Gynecology and Obstetrics.2024; 311(2): 437.     CrossRef
  • A Photothermal Therapy Study Based on Electrospinning Nanofibers Blended and Coated with Polydopamine Nanoparticles
    Chunhong Sui, Yijia Luo, Xiao Xiao, Jiaxue Liu, Xiaotong Shao, Yingxue Xue, Cheng Wang, Wenliang Li
    ChemistrySelect.2023;[Epub]     CrossRef
  • Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction
    Da Eun Lee, Hyeon Woong Kang, So Yi Kim, Myeong Jin Kim, Jae Woong Jeong, Woosol Chris Hong, Sungsoon Fang, Hyung Sun Kim, Yun Sun Lee, Hyo Jung Kim, Joon Seong Park
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • CircLMTK2 Silencing Attenuates Gemcitabine Resistance in Pancreatic Cancer by Sponging miR-485-5p and to Target PAK1
    Yeting Lu, Shuping Zhou, Gong Cheng, Yi Ruan, Yuan Tian, Kaiji Lv, Shuo Han, Xinhua Zhou, Xiangya Ding
    Journal of Oncology.2022; 2022: 1.     CrossRef
  • Effects of Radiotherapy and Chemotherapy on Postoperative Prognosis of Patients Undergoing Radical Surgery for Pancreatic Cancer—Based on SEER Database Analysis
    媛媛 苏
    Advances in Clinical Medicine.2022; 12(10): 9540.     CrossRef
  • Zebrafish Patient-Derived Xenografts Identify Chemo-Response in Pancreatic Ductal Adenocarcinoma Patients
    Alice Usai, Gregorio Di Franco, Margherita Piccardi, Perla Cateni, Luca Emanuele Pollina, Caterina Vivaldi, Enrico Vasile, Niccola Funel, Matteo Palmeri, Luciana Dente, Alfredo Falcone, Dimitri Giunchi, Alessandro Massolo, Vittoria Raffa, Luca Morelli
    Cancers.2021; 13(16): 4131.     CrossRef
  • Hypoxia-Induced ZWINT Mediates Pancreatic Cancer Proliferation by Interacting With p53/p21
    Peng Chen, Zhiwei He, Jie Wang, Jian Xu, Xueyi Jiang, Yankun Chen, Xinyuan Liu, Jianxin Jiang
    Frontiers in Cell and Developmental Biology.2021;[Epub]     CrossRef
  • 7,324 View
  • 153 Download
  • 10 Crossref
Close layer
Breast Cancer
Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL)
Jiyun Lee, Seock-Ah Im, Gun Min Kim, Kyung Hae Jung, Seok Yun Kang, In Hae Park, Jee Hyun Kim, Hee Kyung Ahn, Yeon Hee Park
Cancer Res Treat. 2021;53(3):695-702.   Published online December 17, 2020
DOI: https://doi.org/10.4143/crt.2020.1246
AbstractAbstract PDFPubReaderePub
Purpose
YoungPEARL (KCSG-BR15-10) trial demonstrated a significant progression-free survival (PFS) benefit for premenopausal patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) metastatic breast cancer (MBC) for palbociclib plus exemestane with ovarian function suppression compared to capecitabine. However, the number of tamoxifen-sensitive premenopausal patients was small because most recurrences occurred early during adjuvant endocrine therapy (ET), with tamoxifen being the only drug used; hence, the data for these patients were limited. Here we present a subgroup analysis according to tamoxifen sensitivity from the YoungPEARL study. Materials and Methods Patients were randomized 1:1 to receive palbociclib+ET (oral exemestane 25 mg/day for 28 days, palbociclib 125 mg/day for 21 days, plus leuprolide 3.75 mg subcutaneously every 4 weeks) or chemotherapy (oral capecitabine 1,250 mg/m2 twice daily for 14 days every 3 weeks). Tamoxifen resistance was defined as: relapse while on adjuvant tamoxifen, relapse within 12 months of completing adjuvant tamoxifen, or progression while on first-line tamoxifen within 6 months for MBC.
Results
In total, 184 patients were randomized and 178 were included in the modified intention-to-treat population. PFS improvement in the palbociclib+ET group was observed in tamoxifen-sensitive patients (hazard ratio, 0.38; 95% confidence interval, 0.12 to 1.19). Furthermore, palbociclib+ET prolonged median PFS compared with capecitabine in tamoxifen-sensitive (20.5 months vs. 12.6 months) and tamoxifen-resistant (20.1 months vs. 14.5 months) patients. Palbociclib+ET demonstrated a higher rate of objective response, disease control, and clinical benefit in tamoxifen-sensitive patients. Conclusion This post hoc exploratory analysis suggests that palbociclib+ET is a promising therapeutic option for premenopausal HR+/HER2– MBC patients irrespective of tamoxifen sensitivity.

Citations

Citations to this article as recorded by  
  • Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China
    Jiao Yang, Bing Zhao, Xiaoling Ling, Donghui Li, Jiuda Zhao, Yonggang Lv, Guangxi Wang, Xinlan Liu, Nanlin Li, Jin Yang
    BMC Cancer.2023;[Epub]     CrossRef
  • 7,508 View
  • 278 Download
  • 2 Web of Science
  • 1 Crossref
Close layer
Prospective Validation of The Korean Cancer Study Group Geriatric Score (KG)-7, a Novel Geriatric Screening Tool, in Older Patients with Advanced Cancer Undergoing First-line Palliative Chemotherapy
Jin Won Kim, Se Hyun Kim, Yun-Gyoo Lee, In Gyu Hwang, Jin Young Kim, Su-Jin Koh, Yoon Ho Ko, Seong Hoon Shin, In Sook Woo, Soojung Hong, Tae-Yong Kim, Ji Yeon Baek, Hyun Jung Kim, Hyo Jung Kim, Myung Ah Lee, Jung Hye Kwon, Yong Sang Hong, Hun-Mo Ryoo, Kyung Hee Lee, Jee Hyun Kim
Cancer Res Treat. 2019;51(3):1249-1256.   Published online January 2, 2019
DOI: https://doi.org/10.4143/crt.2018.451
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to prospectively validate the Korean Cancer Study Group Geriatric Score (KG)-7, a novel geriatric screening tool, in older patients with advanced cancer planned to undergo first-line palliative chemotherapy.
Materials and Methods
Participants answered the KG-7 questionnaire before undergoing geriatric assessment (GA) and first-line palliative chemotherapy. The performance of KG-7 was evaluated by calculating the sensitivity (SE), specificity (SP), positive and negative predictive value (PPV and NPV), balanced accuracy (BA), and area under the curve (AUC).
Results
The baseline GA and KG-7 results were collected from 301 patients. The median age was 75 years (range, 70 to 93 years). Abnormal GA was documented in 222 patients (73.8%). Based on the ≤ 5 cut-off value of KG-7 for abnormal GA, abnormal KG-7 score was shown in 200 patients (66.4%). KG-7 showed SE, SP, PPV, NPV, and BA of 75.7%, 59.7%, 84.4%, 46.0%, and 67.7%, respectively; AUC was 0.745 (95% confidence interval, 0.687 to 0.803). Furthermore, patients with higher KG-7 scores showed significantly longer survival (p=0.006).
Conclusion
KG-7 appears to be adequate in identifying patients with abnormal GA prospectively. Hence, KG-7 can be a useful screening tool for Asian countries with limited resources and high patient volume.

Citations

Citations to this article as recorded by  
  • Comparison of two frailty screening tools in older patients with colorectal cancer
    Han Zhao, Xinlin Lu, Senshuang Zheng, Danmei Wei, Lizhong Zhao, Yuan Wang, Geertruida H. de Bock, Wenli Lu
    BMC Geriatrics.2023;[Epub]     CrossRef
  • Prevalence and Predictive Factors for Upfront Dose Reduction of the First Cycle of First-Line Chemotherapy in Older Adults with Metastatic Solid Cancer: Korean Cancer Study Group (KCSG) Multicenter Study
    In Gyu Hwang, Minsuk Kwon, Jin Won Kim, Se Hyun Kim, Yun-Gyoo Lee, Jin Young Kim, Su-Jin Koh, Yoon Ho Ko, Seong Hoon Shin, Soojung Hong, Tae-Yong Kim, Sun Young Kim, Hyun Jung Kim, Hyo Jung Kim, Myung Ah Lee, Jung Hye Kwon, Yong Sang Hong, Kyung Hee Lee,
    Cancers.2021; 13(2): 331.     CrossRef
  • A single-arm feasibility study of gradual dose de-escalation of antiemetic dexamethasone for older patients receiving chemotherapy
    Koung Jin Suh, Seonghae Yoon, Jin Won Kim, Seo Hyun Yoon, Ji-Won Kim, Se Hyun Kim, Yu Jung Kim, Keun-Wook Lee, Jong Seok Lee, Jee Hyun Kim
    Journal of Geriatric Oncology.2021; 12(6): 922.     CrossRef
  • Predictive Value of Geriatric Oncology Screening and Geriatric Assessment in Older Patients with Solid Cancers: Protocol for a Danish prospective cohort study (PROGNOSIS-G8)
    Helena Møgelbjerg Ditzel, Ann-Kristine Weber Giger, Cecilia Margareta Lund, Henrik Jørn Ditzel, Afsaneh Mohammadnejad, Per Pfeiffer, Jesper Ryg, Trine Lembrecht Jørgensen, Marianne Ewertz
    Journal of Geriatric Oncology.2021; 12(8): 1270.     CrossRef
  • The Globalization of Geriatric Oncology: From Data to Practice
    Ravindran Kanesvaran, Supriya Mohile, Enrique Soto-Perez-de-Celis, Harpreet Singh
    American Society of Clinical Oncology Educational Book.2020; (40): e107.     CrossRef
  • 9,770 View
  • 180 Download
  • 4 Web of Science
  • 5 Crossref
Close layer
Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer
Junghoon Shin, Jin-Haeng Chung, Se Hyun Kim, Kyu Sang Lee, Koung Jin Suh, Ji Yun Lee, Ji-Won Kim, Jeong-Ok Lee, Jin-Won Kim, Yu-Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Jong-Seok Lee
Cancer Res Treat. 2019;51(3):1086-1097.   Published online November 5, 2018
DOI: https://doi.org/10.4143/crt.2018.537
AbstractAbstract PDFPubReaderePub
Purpose
Programmed death-1 (PD-1)/PD-1 ligand (PD-L1) axis blockades have revolutionized the treatment of advanced non-small cell lung cancer (NSCLC). We assessed the effect of platinum-based chemotherapy on tumor PD-L1 expression and its clinical implications.
Materials and Methods
We used immunohistochemistry to retrospectively evaluate the percentage of tumor cells with membranous PD-L1 staining (tumor proportion score) in paired tumor specimens obtained before and after platinum-based neoadjuvant chemotherapy (NACT) in 86 patients with NSCLC. We analyzed the correlation between the change in PD-L1 tumor proportion score and clinicopathologic characteristics, response to NACT, and survival.
Results
The PD-L1 tumor proportion score increased in a significant proportion of patients with NSCLC after platinum-based NACT (Wilcoxon signed-rank test, p=0.002). That pattern was consistent across clinically defined subgroups except for patients with partial response to NACT. Tumors from 26 patients (30.2%) were PD-L1‒negative before NACT but PD-L1-positive after NACT, whereas the reverse pattern occurred in six patients (7%) (McNemar’s test, p < 0.001). Increase in PD-L1 tumor proportion score was significantly associated with lack of response to NACT (Fisher exact test, p=0.015). There was a tendency, albeit not statistically significant, for patients with an increase in PD-L1 tumor proportion score to have shorter survival.
Conclusion
Tumor PD-L1 expression increased after platinum-based NACT in a significant proportion of patients with NSCLC. Increase in tumor PD-L1 expression may predict poor clinical outcome.

Citations

Citations to this article as recorded by  
  • Prevalence and Clinical Association of CD276 (B7-H3) Expression in Pleural Mesothelioma: Results From the European Thoracic Platform Mesoscape Project
    Martina Haberecker, Jan H. Rüschoff, Charitini Andriakopoulou, Steven G. Gray, Kristiaan Nackaerts, Marc De Perrot, Luka Brcic, Ernest Nadal, Sotirios Tsimpoukis, Luca Ampollini, Joachim G. Aerts, Michaela B. Kirschner, Kim Monkhorst, Birgit Weynand, Fate
    JCO Precision Oncology.2025;[Epub]     CrossRef
  • Selenium-containing compounds, selenium nanoparticles and selenoproteins in the prevention and treatment of lung cancer
    Elena G. Varlamova
    Journal of Trace Elements in Medicine and Biology.2025; 88: 127620.     CrossRef
  • Potential Predictive Immune and Metabolic Biomarkers of Tumor Microenvironment Regarding Pathological and Clinical Response in Esophageal Cancer After Neoadjuvant Chemoradiotherapy: A Systematic Review
    H. H. Wang, E. N. Steffens, G. Kats-Ugurlu, B. van Etten, J. G. M. Burgerhof, G. A. P. Hospers, J. T. M. Plukker
    Annals of Surgical Oncology.2024; 31(1): 433.     CrossRef
  • Redetermination of PD-L1 expression after chemio-radiation in locally advanced PDL1 negative NSCLC patients: retrospective multicentric analysis
    Patrizia Ciammella, Salvatore Cozzi, Paolo Borghetti, Marco Galaverni, Valerio Nardone, Maria Paola Ruggieri, Matteo Sepulcri, Vieri Scotti, Alessio Bruni, Francesca Zanelli, Roberto Piro, Elena Tagliavini, Andrea Botti, Federico Iori, Emanuele Alì, Chiar
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • First exploration of the on-treatment changes in tumor and organ uptake of a radiolabeled anti PD-L1 antibody during chemoradiotherapy in patients with non-small cell lung cancer using whole body PET
    Johanna E E Pouw, Sayed M S Hashemi, Marc C Huisman, Jessica E Wijngaarden, Maarten Slebe, Daniela E Oprea-Lager, Gerben J C Zwezerijnen, Danielle Vugts, Ezgi B Ulas, Tanja D de Gruijl, Teodora Radonic, Suresh Senan, C Willemien Menke-van der Houven van O
    Journal for ImmunoTherapy of Cancer.2024; 12(2): e007659.     CrossRef
  • Use of non-small cell lung cancer multicellular tumor spheroids to study the impact of chemotherapy
    Pauline Hulo, Sophie Deshayes, Judith Fresquet, Anne-Laure Chéné, Stéphanie Blandin, Nicolas Boisgerault, Jean-François Fonteneau, Lucas Treps, Marc G Denis, Jaafar Bennouna, Delphine Fradin, Elvire Pons-Tostivint, Christophe Blanquart
    Respiratory Research.2024;[Epub]     CrossRef
  • Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer
    Ji Won Woo, Eun Kyung Han, Koung Jin Suh, Se Hyun Kim, Jee Hyun Kim, So Yeon Park
    Breast Cancer Research and Treatment.2024; 207(2): 301.     CrossRef
  • Transforming Lung Cancer Management: A Promising Case Study of Immune Checkpoint Inhibitor Success Following a Multidisciplinary Approach
    Tadashi Nishimura, Hajime Fujimoto, Takumi Fujiwara, Tomohito Okano, Taro Yasuma, Esteban C. Gabazza, Hidenori Ibata, Tetsu Kobayashi
    Diagnostics.2024; 14(19): 2159.     CrossRef
  • Cryoablation plus chemotherapy regimen enhance anti-tumor immune response in a mouse model of Lewis lung cancer
    Hua Duan, Li Yang, Xueni Fang, Shaohua Yan, Yang Cao, Bingli Qiao, Tian Zhou, Kaiwen Hu
    International Journal of Hyperthermia.2024;[Epub]     CrossRef
  • Increased Tumor Mutation Burden Levels and Sensitivity of Non–Small Cell Lung Cancer to PD-L1 Blockade—Reply
    Biagio Ricciuti, Xinan Wang, Mark M. Awad
    JAMA Oncology.2023; 9(4): 570.     CrossRef
  • Add-On Effect of Hemagglutinating Virus of Japan Envelope Combined with Chemotherapy or Immune Checkpoint Inhibitor against Malignant Pleural Mesothelioma: An In Vivo Study
    Kazuma Sakura, Masao Sasai, Soichiro Funaki, Yasushi Shintani, Meinoshin Okumura, Yasufumi Kaneda
    Cancers.2023; 15(3): 929.     CrossRef
  • Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data
    WeiQing Venus So, David Dejardin, Eva Rossmann, Jehad Charo
    Journal for ImmunoTherapy of Cancer.2023; 11(2): e006464.     CrossRef
  • Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14
    D. König, S. Savic Prince, S. Hayoz, P. Zens, S. Berezowska, W. Jochum, E. Stauffer, V. Braunersreuther, B. Trachsel, S. Thierstein, M. Mark, S. Schmid, A. Curioni-Fontecedro, A. Addeo, I. Opitz, M. Guckenberger, M. Früh, D.C. Betticher, H.-B. Ris, R. Stu
    ESMO Open.2023; 8(4): 101595.     CrossRef
  • Poliovirus receptor (PVR) mediates carboplatin-induced PD-L1 expression in non-small-cell lung cancer cells
    Chen Fu, Zongcai Liu, Taixue An, Haixia Li, Xiumei Hu, Xin Li, Xinyao Liu, Danjuan Wu, Ruyi Zhang, Kui Li, Yurong Qiu, Haifang Wang
    Biochimica et Biophysica Acta (BBA) - General Subjects.2023; 1867(10): 130439.     CrossRef
  • Remarkable Response to Immune Checkpoint Inhibitor Monotherapy in an EGFR-Mutant Pulmonary Adenocarcinoma Patient With 0% Expression of PD-L1
    Tetsuo Fujita, Hiroyuki Amano, Makoto Nakamura, Satoshi Hirano, Sukeyuki Nakamura
    Journal of Thoracic Oncology.2023; 18(9): e93.     CrossRef
  • Effect of Chemotherapeutics on In Vitro Immune Checkpoint Expression in Non-Small Cell Lung Cancer
    Yu Zhao, Zhe Wang, Xiuhuan Shi, Ting Liu, Wenwen Yu, Xiubao Ren, Hua Zhao
    Technology in Cancer Research & Treatment.2023;[Epub]     CrossRef
  • The Role of Regulatory T Cells in Cancer Treatment Resistance
    Anna Dąbrowska, Magdalena Grubba, Amar Balihodzic, Olga Szot, Bartosz Kamil Sobocki, Adrian Perdyan
    International Journal of Molecular Sciences.2023; 24(18): 14114.     CrossRef
  • Redirecting Chemotherapeutics to the Endoplasmic Reticulum Increases Tumor Immunogenicity and Potentiates Anti‐PD‐L1 Therapy
    Yucheng Xiang, Liqiang Chen, Chendong Liu, Xiaoli Yi, Lian Li, Yuan Huang
    Small.2022;[Epub]     CrossRef
  • FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell–Mediated Bladder Cancer Immune Surveillance
    Weiqiang Jing, Ganyu Wang, Zhiwei Cui, Gaozhong Xiong, Xin Jiang, Yue Li, Wushan Li, Bo Han, Shouzhen Chen, Benkang Shi
    Cancer Research.2022; 82(1): 114.     CrossRef
  • The immune modifying effects of chemotherapy and advances in chemo-immunotherapy
    Daniel R. Principe, Suneel D. Kamath, Murray Korc, Hidayatullah G. Munshi
    Pharmacology & Therapeutics.2022; 236: 108111.     CrossRef
  • Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study
    S. Park, J.-M. Sun, Y.-L. Choi, D. Oh, H.K. Kim, T. Lee, S.A. Chi, S.-H. Lee, Y.S. Choi, S.-H. Jung, M.-J. Ahn, Y.C. Ahn, K. Park, Y.M. Shim
    ESMO Open.2022; 7(1): 100385.     CrossRef
  • Analytical validation and initial clinical testing of quantitative microscopic evaluation for PD-L1 and HLA I expression on circulating tumor cells from patients with non-small cell lung cancer
    Jennifer L. Schehr, Nan Sethakorn, Zachery D. Schultz, Camila I. Hernandez, Rory M. Bade, Diego Eyzaguirre, Anupama Singh, David J. Niles, Leslie Henderson, Jay W. Warrick, Scott M. Berry, Kaitlin E. Sundling, David J. Beebe, Ticiana A. Leal, Joshua M. La
    Biomarker Research.2022;[Epub]     CrossRef
  • Translational Learnings in the Development of Chemo-Immunotherapy Combination to Bypass the Cold Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma
    Hélène Kaplon
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Cost-effectiveness analyses of durvalumab consolidation therapy versus no consolidation therapy after chemoradiotherapy in stage-III NSCLC
    Salman Hussain, Jitka Klugarova, Miloslav Klugar
    Lung Cancer.2022; 170: 11.     CrossRef
  • Efficacy comparison of immune treating strategies for NSCLC patients with negative PD-L1 expression
    Kaiyue Ding, Minhan Yi, Hui Liang, Zhongkui Li, Yuan Zhang
    Expert Review of Clinical Immunology.2022; 18(7): 759.     CrossRef
  • Dual inhibition of TGFβ signaling and CSF1/CSF1R reprograms tumor-infiltrating macrophages and improves response to chemotherapy via suppressing PD-L1
    Tsung-Wei Chen, Wei-Ze Hung, Shu-Fen Chiang, William Tzu-Liang Chen, Tao-Wei Ke, Ji-An Liang, Chih-Yang Huang, Pei-Chen Yang, Kevin Chih-Yang Huang, K.S. Clifford Chao
    Cancer Letters.2022; 543: 215795.     CrossRef
  • SP142 PD-L1 Assays in Multiple Samples from the Same Patients with Early or Advanced Triple-Negative Breast Cancer
    Seung Ho Baek, Jee Hung Kim, Soong June Bae, Jung Hwan Ji, Yangkyu Lee, Joon Jeong, Yoon Jin Cha, Sung Gwe Ahn
    Cancers.2022; 14(13): 3042.     CrossRef
  • Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate
    Taotao Zhou, Robert Mahn, Christian Möhring, Farsaneh Sadeghlar, Carsten Meyer, Marieta Toma, Barbara Kreppel, Markus Essler, Tim Glowka, Hanno Matthaei, Jörg C. Kalff, Christian P. Strassburg, Maria A. Gonzalez-Carmona
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Is there a place for chemotherapy in first line of treatment for metastatic NSCLC in era of immunotherapy?
    D. I. Yudin, K. K. Laktionov
    Medical alphabet.2022; (13): 18.     CrossRef
  • The effect of neoadjuvant therapy on PD-L1 expression and CD8+lymphocyte density in non-small cell lung cancer
    Philipp Zens, Corina Bello, Amina Scherz, Michael von Gunten, Adrian Ochsenbein, Ralph A. Schmid, Sabina Berezowska
    Modern Pathology.2022; 35(12): 1848.     CrossRef
  • MicroRNAs and Drug Resistance in Non-Small Cell Lung Cancer: Where Are We Now and Where Are We Going
    Roberto Cuttano, Miriam Kuku Afanga, Fabrizio Bianchi
    Cancers.2022; 14(23): 5731.     CrossRef
  • miRNome profiling of lung cancer metastases revealed a key role for miRNA-PD-L1 axis in the modulation of chemotherapy response
    Roberto Cuttano, Tommaso Colangelo, Juliana Guarize, Elisa Dama, Maria Pia Cocomazzi, Francesco Mazzarelli, Valentina Melocchi, Orazio Palumbo, Elena Marino, Elena Belloni, Francesca Montani, Manuela Vecchi, Massimo Barberis, Paolo Graziano, Andrea Pasqui
    Journal of Hematology & Oncology.2022;[Epub]     CrossRef
  • PD‐1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma
    Tahlia Scheinberg, Anna Lomax, Martin Tattersall, David Thomas, Geoff McCowage, Michael Sullivan, Rooshdiya Karim, Peter P. Luk, Annabelle Mahar, Fiona Bonar, Vivek A. Bhadri
    Cancer Reports.2021;[Epub]     CrossRef
  • PD‐L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced non‐small cell lung cancer?
    Aoran Dong, Yiming Zhao, Zhihua Li, Hai Hu
    The Journal of Gene Medicine.2021;[Epub]     CrossRef
  • Biomarkers predicting the response to chemotherapy and the prognosis in patients with esophageal squamous cell carcinoma
    Seiya Inoue, Takahiro Yoshida, Takeshi Nishino, Masakazu Goto, Mariko Aoyama, Naoya Kawakita, Yota Yamamoto, Furukita Yoshihito, Hiromitsu Takizawa, Akira Tangoku
    General Thoracic and Cardiovascular Surgery.2021; 69(3): 525.     CrossRef
  • Patient-Reported Outcomes with Durvalumab by PD-L1 Expression and Prior Chemoradiotherapy-Related Variables in Unresectable Stage III Non-Small-Cell Lung Cancer
    Marina C Garassino, Luis Paz-Ares, Rina Hui, Corinne Faivre-Finn, Alex Spira, David Planchard, Mustafa Özgüroğlu, Davey Daniel, David Vicente, Shuji Murakami, Corey Langer, Suresh Senan, David Spigel, Anna Rydén, Yiduo Zhang, Cathy O'Brien, Phillip A Denn
    Future Oncology.2021; 17(10): 1165.     CrossRef
  • Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer
    S. Sugawara, J.-S. Lee, J.-H. Kang, H.R. Kim, N. Inui, T. Hida, K.H. Lee, T. Yoshida, H. Tanaka, C.-T. Yang, M. Nishio, Y. Ohe, T. Tamura, N. Yamamoto, C.-J. Yu, H. Akamatsu, Y. Namba, N. Sumiyoshi, K. Nakagawa
    Annals of Oncology.2021; 32(9): 1137.     CrossRef
  • Temporal evolution of programmed death-ligand 1 expression in patients with non-small cell lung cancer
    Chang Hyun Nam, Jaemoon Koh, Chan-Young Ock, Miso Kim, Bhumsuk Keam, Tae Min Kim, Yoon Kyung Jeon, Dong-Wan Kim, Doo Hyun Chung, Dae Seog Heo
    The Korean Journal of Internal Medicine.2021; 36(4): 975.     CrossRef
  • Methylseleninic acid overcomes programmed death‐ligand 1‐mediated resistance of prostate cancer and lung cancer
    Wenli Hu, Yurong Ma, Chong Zhao, Shutao Yin, Hongbo Hu
    Molecular Carcinogenesis.2021; 60(11): 746.     CrossRef
  • Immunological Status of Bladder Cancer Patients Based on Urine Leukocyte Composition at Radical Cystectomy
    Elisabet Cantó, Óscar Rodríguez Faba, Carlos Zamora, Maria Mulet, Maria Soledad Garcia-Cuerva, Ana Palomino, Georgia Anguera, Alberto Breda, Pablo Maroto, Sílvia Vidal
    Biomedicines.2021; 9(9): 1125.     CrossRef
  • Ex vivo expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells through different receptor-ligand interactions
    Daun Jung, Young Seok Baek, In Jee Lee, Ki Yeon Kim, Heejoo Jang, Sohyun Hwang, Jieun Jung, Yong-wha Moon, Kyung-Soon Park, Yong-Soo Choi, Hee Jung An
    Journal of Experimental & Clinical Cancer Research.2021;[Epub]     CrossRef
  • Prognostic significance of T‐cell–inflamed gene expression profile and PD‐L1 expression in patients with esophageal cancer
    Torben Steiniche, Sun Young Rha, Hyun Cheol Chung, Jeanette Baehr Georgsen, Morten Ladekarl, Marianne Nordsmark, Marie Louise Jespersen, Hyo Song Kim, Hyunki Kim, Carly Fein, Laura H. Tang, Ting Wu, Matthew J. Marton, Senaka Peter, David P. Kelsen, Geoffr
    Cancer Medicine.2021; 10(23): 8365.     CrossRef
  • A novel form of immunotherapy using antigen peptides conjugated on PD-L1 antibody
    Eun Ji Lee, Gun-Young Jang, Sung Eun Lee, Ji won Lee, Hee Dong Han, Yeong-Min Park, Tae Heung Kang
    Immunology Letters.2021;[Epub]     CrossRef
  • Assessment of the expression of the immune checkpoint molecules PD‐1, CTLA4, TIM‐3 and LAG‐3 across different cancers in relation to treatment response, tumor‐infiltrating immune cells and survival
    Lei Tu, Renguo Guan, Hanting Yang, Yu Zhou, Weifeng Hong, Liheng Ma, Guangzhe Zhao, Min Yu
    International Journal of Cancer.2020; 147(2): 423.     CrossRef
  • Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis
    Jiahang Mo, Xiao Hu, Lihu Gu, Bangsheng Chen, Parikshit Asutosh Khadaroo, Zefeng Shen, Lei Dong, Yuqi Lv, Marylin Nyaradzo Chitumba, Jiequan Liu
    World Journal of Surgical Oncology.2020;[Epub]     CrossRef
  • Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy
    Kathrin Gennen, Lukas Käsmann, Julian Taugner, Chukwuka Eze, Monika Karin, Olarn Roengvoraphoj, Jens Neumann, Amanda Tufman, Michael Orth, Simone Reu, Claus Belka, Farkhad Manapov
    Radiation Oncology.2020;[Epub]     CrossRef
  • PD-L1 induction in tumor tissue after hypofractionated thoracic radiotherapy for non-small cell lung cancer
    Jaanika Narits, Hannes Tamm, Jana Jaal
    Clinical and Translational Radiation Oncology.2020; 22: 83.     CrossRef
  • Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy
    Yun Liang, Minghua Yu, Caiyun Zhou, Xiaojun Zhu
    Diagnostic Pathology.2020;[Epub]     CrossRef
  • Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench
    Rui Jin, Jing Zhao, Lexin Xia, Qin Li, Wen Li, Ling Peng, Yang Xia
    Therapeutic Advances in Medical Oncology.2020;[Epub]     CrossRef
  • Independent Prognostic Value of Intratumoral Heterogeneity and Immune Response Features by Automated Digital Immunohistochemistry Analysis in Early Hormone Receptor-Positive Breast Carcinoma
    Dovile Zilenaite, Allan Rasmusson, Renaldas Augulis, Justinas Besusparis, Aida Laurinaviciene, Benoit Plancoulaine, Valerijus Ostapenko, Arvydas Laurinavicius
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
    Lorenzo Galluzzi, Juliette Humeau, Aitziber Buqué, Laurence Zitvogel, Guido Kroemer
    Nature Reviews Clinical Oncology.2020; 17(12): 725.     CrossRef
  • Re-biopsy after first line treatment in advanced NSCLC can reveal changes in PD-L1 expression
    Malene Støchkel Frank, Uffe Bødtger, Asbjørn Høegholm, Inger Merete Stamp, Julie Gehl
    Lung Cancer.2020; 149: 23.     CrossRef
  • The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?
    Giuseppe Lamberti, Monia Sisi, Elisa Andrini, Arianna Palladini, Francesca Giunchi, Pier-Luigi Lollini, Andrea Ardizzoni, Francesco Gelsomino
    Cancers.2020; 12(11): 3129.     CrossRef
  • The Dichotomous Role of Bone Marrow Derived Cells in the Chemotherapy-Treated Tumor Microenvironment
    Avital Vorontsova, Tal Kan, Ziv Raviv, Yuval Shaked
    Journal of Clinical Medicine.2020; 9(12): 3912.     CrossRef
  • Adjuvant Chemotherapy Increases Programmed Death-Ligand 1 (PD-L1) Expression in Non–small Cell Lung Cancer Recurrence
    Max Lacour, Stefanie Hiltbrunner, Seok-Yun Lee, Alex Soltermann, Elisabeth Jane Rushing, Davide Soldini, Walter Weder, Alessandra Curioni-Fontecedro
    Clinical Lung Cancer.2019; 20(5): 391.     CrossRef
  • PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future
    Hyojin Kim, Jin-Haeng Chung
    Journal of Pathology and Translational Medicine.2019; 53(4): 199.     CrossRef
  • 11,690 View
  • 485 Download
  • 61 Web of Science
  • 56 Crossref
Close layer
Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma
Changhoon Yoo, Jihoon Kang, Ho Yeong Lim, Jee Hyun Kim, Myung-Ah Lee, Kyung-Hun Lee, Tae-You Kim, Baek-Yeol Ryoo
Cancer Res Treat. 2019;51(2):510-518.   Published online June 13, 2018
DOI: https://doi.org/10.4143/crt.2018.226
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The signal transducer and activator of transcription 3 (STAT3) signaling pathway might be a promising therapeutic target for hepatocellular carcinoma (HCC).
Materials and Methods
This study was a multicenter, open-label, non-comparative, dose escalating phase I study of OPB-111077, an oral STAT3 inhibitor, in patients with advanced HCC who failed on sorafenib. Continuous dosing (daily administration, 50 to 400 mg) and intermittent dosing (4-days on/3-days off administration: 300 to 900 mg) regimens were evaluated and the dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), and recommended dose (RD) were the primary endpoints.
Results
A total of 33 patients (19 for continuous dosing and 14 for intermittent dosing) were enrolled. One patient experienced a DLT with grade 3 dizziness, but the MTD was identified in neither the continuous nor the intermittent dosing cohorts. The RDs were determined to be 250 mg for the continuous dosing regimen and 600 mg for the intermittent dosing regimen. There was no treatment-related death; five patients (15.2%) had grade 3-4 toxicities including thrombocytopenia (6%), fatigue (3%), and dizziness (3%). No patients achieved complete or partial responses and the median progression-free survival was 1.4 months (95% confidence interval, 0.8 to 2.8).
Conclusion
OPB-111077 was well tolerated in patients with advanced HCC after sorafenib failure, but only showed limited preliminary efficacy outcomes. Further investigation of the role of the STAT3 signaling pathway in HCC and the development of biomarkers for STAT3 inhibitors are warranted.

Citations

Citations to this article as recorded by  
  • Mechanisms and therapeutic prospect of the JAK-STAT signaling pathway in liver cancer
    JunJun Jia, Xuelian Zhou, Qingfei Chu
    Molecular and Cellular Biochemistry.2025; 480(1): 1.     CrossRef
  • Structural Optimization and Characterization of Highly Potent and Selective STAT3 Inhibitors for the Treatment of Triple Negative Breast Cancer
    Wangrui Jin, Yuzhu Zhang, Baozhen Wang, Zhaoyong Kang, Huachao Li, Jingfeng Song, Yihua Chen, Hai Xiong, Jing Chen
    European Journal of Medicinal Chemistry.2025; : 117332.     CrossRef
  • Hepatocellular carcinoma: signaling pathways and therapeutic advances
    Jiaojiao Zheng, Siying Wang, Lei Xia, Zhen Sun, Kui Ming Chan, René Bernards, Wenxin Qin, Jinhong Chen, Qiang Xia, Haojie Jin
    Signal Transduction and Targeted Therapy.2025;[Epub]     CrossRef
  • Precision therapeutic targets for HPV-positive cancers: an overview and new insights
    Yixi Huang, Jiayi Wang, Wenbin Yang, Feifei Hou, Xiaodong Feng
    Infectious Agents and Cancer.2025;[Epub]     CrossRef
  • Targeting JAK2/STAT3 for the treatment of cancer: A review on recent advancements in molecular development using structural analysis and SAR investigations
    Rupali Kohal, Priya Bisht, Ghanshyam Das Gupta, Sant Kumar Verma
    Bioorganic Chemistry.2024; 143: 107095.     CrossRef
  • Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery
    Yamei Hu, Zigang Dong, Kangdong Liu
    Journal of Experimental & Clinical Cancer Research.2024;[Epub]     CrossRef
  • Hepatocellular Carcinoma: Old and Emerging Therapeutic Targets
    Greta Pessino, Claudia Scotti, Maristella Maggi
    Cancers.2024; 16(5): 901.     CrossRef
  • Isoalantolactone exerts anti‐melanoma effects via inhibiting PI3K/AKT/mTOR and STAT3 signaling in cell and mouse models
    Jun‐Kui Li, Xiao‐Li Jiang, Zhu Zhang, Wen‐Qing Chen, Jun‐Jie Peng, Bin Liu, Pei‐Li Zhu, Ken‐Kin‐Lam Yung
    Phytotherapy Research.2024; 38(6): 2800.     CrossRef
  • Prognostic and therapeutic potential of STAT3: Opportunities and challenges in targeting HPV-mediated cervical carcinogenesis
    Divya Janjua, Kulbhushan Thakur, Nikita Aggarwal, Apoorva Chaudhary, Joni Yadav, Arun Chhokar, Tanya Tripathi, Udit Joshi, Anna Senrung, Alok Chandra Bharti
    Critical Reviews in Oncology/Hematology.2024; 197: 104346.     CrossRef
  • Signaling pathways in liver cancer: pathogenesis and targeted therapy
    Yangtao Xue, Yeling Ruan, Yali Wang, Peng Xiao, Junjie Xu
    Molecular Biomedicine.2024;[Epub]     CrossRef
  • STAT3: Key targets of growth-promoting receptor positive breast cancer
    Rui-yuan Jiang, Jia-yu Zhu, Huan-ping Zhang, Yuan Yu, Zhi-xin Dong, Huan-huan Zhou, Xiaojia Wang
    Cancer Cell International.2024;[Epub]     CrossRef
  • Discovery, Optimization, and Evaluation of Novel N-(Benzimidazol-5-yl)-1,3,4-thiadiazol-2-amine Analogues as Potent STAT3 Inhibitors for Cancer Treatment
    Ru Wang, Ting-Ting Du, Wen-Qiang Liu, Yi-Chen Liu, Ya-Dong Yang, Jin-Ping Hu, Ming Ji, Bei-Bei Yang, Li Li, Xiao-Guang Chen
    Journal of Medicinal Chemistry.2023; 66(17): 12373.     CrossRef
  • Polyphenols as potential metabolism mechanisms regulators in liver protection and liver cancer prevention
    Shuangfeng Li, Shuangshuang Yin, Hui Ding, Yingying Shao, Shiyue Zhou, Weiling Pu, Lifeng Han, Tao Wang, Haiyang Yu
    Cell Proliferation.2023;[Epub]     CrossRef
  • Eupalinolide J Inhibits Cancer Metastasis by Promoting STAT3 Ubiquitin-Dependent Degradation
    Hongtao Hu, Haoyang Bai, Lili Huang, Bo Yang, Huajun Zhao
    Molecules.2023; 28(7): 3143.     CrossRef
  • Discovery of a Highly Potent and Orally Bioavailable STAT3 Dual Phosphorylation Inhibitor for Pancreatic Cancer Treatment
    Peng He, Aiwu Bian, Ying Miao, Wangrui Jin, Huang Chen, Jia He, Liting Li, Yue Sun, Jiangnan Ye, Mingyao Liu, Zhengfang Yi, Wenbo Zhou, Yihua Chen
    Journal of Medicinal Chemistry.2022; 65(22): 15487.     CrossRef
  • STAT3 pathway in cancers: Past, present, and future
    Han‐Qi Wang, Qi‐Wen Man, Fang‐Yi Huo, Xin Gao, Hao Lin, Su‐Ran Li, Jing Wang, Fu‐Chuan Su, Lulu Cai,, Yi Shi, Bing Liu,, Lin‐Lin Bu
    MedComm.2022;[Epub]     CrossRef
  • Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook
    Yinjie Fan, Hang Xue, Huachuan Zheng
    Journal of Hepatocellular Carcinoma.2022; Volume 9: 233.     CrossRef
  • Constant Activation of STAT3 Contributes to the Development of Adenomyosis in Females
    Takehiro Hiraoka, Yasushi Hirota, Shizu Aikawa, Rei Iida, Chihiro Ishizawa, Tetsuaki Kaku, Tomoyuki Hirata, Yamato Fukui, Shun Akaeda, Mitsunori Matsuo, Ryoko Shimizu-Hirota, Norihiko Takeda, Yutaka Osuga
    Endocrinology.2022;[Epub]     CrossRef
  • Biomarker‑driven phase Ib clinical trial of OPB‑111077 in acute myeloid leukemia
    Joaquín Martínez‑López, Pau Montesinos, Nieves López‑Muñoz, Rosa Ayala, Pilar Martínez‑Sánchez, Julian Gorrochategui, José Rojas‑Rudilla, Daniel Primo, Juan-Miguel Bergua‑Burgues, María Calbacho, Evelyn Acuña‑Cruz, José Pérez‑Simón, Adolfo De La Fuente, J
    Medicine International.2022;[Epub]     CrossRef
  • Novel STAT3 Inhibitors Targeting STAT3 Dimerization by Binding to the STAT3 SH2 Domain
    Yaping Hua, Xing Yuan, Yun-heng Shen, Jinxin Wang, Waqas Azeem, Shuo Yang, Alexandra Gade, Seyed Mohammad Lellahi, Anne Margrete Øyan, Xisong Ke, Wei-dong Zhang, Karl-Henning Kalland
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Discovery of a Novel Potent STAT3 Inhibitor HP590 with Dual p-Tyr705/Ser727 Inhibitory Activity for Gastric Cancer Treatment
    Peng He, Ying Miao, Yue Sun, Aiwu Bian, Wangrui Jin, Huang Chen, Jiangnan Ye, Jia He, Yangrui Peng, Haijun Gu, Mingyao Liu, Zhengfang Yi, Yihua Chen
    Journal of Medicinal Chemistry.2022; 65(19): 12650.     CrossRef
  • STAT3 and Its Targeting Inhibitors in Oral Squamous Cell Carcinoma
    Mingjing Jiang, Bo Li
    Cells.2022; 11(19): 3131.     CrossRef
  • NAFLD and HBV interplay - related mechanisms underlying liver disease progression
    Evanthia Tourkochristou, Stelios F. Assimakopoulos, Konstantinos Thomopoulos, Markos Marangos, Christos Triantos
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • An update on investigational therapies that target STAT3 for the treatment of cancer
    Matteo Santoni, Francesca Miccini, Alessia Cimadamore, Francesco Piva, Francesco Massari, Liang Cheng, Antonio Lopez-Beltran, Rodolfo Montironi, Nicola Battelli
    Expert Opinion on Investigational Drugs.2021; 30(3): 245.     CrossRef
  • Rational drug design of benzothiazole-based derivatives as potent signal transducer and activator of transcription 3 (STAT3) signaling pathway inhibitors
    Dingding Gao, Nan Jin, Yixian Fu, Yueyue Zhu, Yujie Wang, Ting Wang, Yuehong Chen, Mingming Zhang, Qiang Xiao, Min Huang, Yingxia Li
    European Journal of Medicinal Chemistry.2021; 216: 113333.     CrossRef
  • NAFLD-Associated HCC: Progress and Opportunities
    Daniel Geh, Quentin M Anstee, Helen L Reeves
    Journal of Hepatocellular Carcinoma.2021; Volume 8: 223.     CrossRef
  • The therapeutic potential of mitochondrial toxins
    Manabu Kawada, Masahide Amemiya, Junjiro Yoshida, Tomokazu Ohishi
    The Journal of Antibiotics.2021; 74(10): 696.     CrossRef
  • Advances of Targeted Therapy for Hepatocellular Carcinoma
    Mengke Niu, Ming Yi, Ning Li, Kongju Wu, Kongming Wu
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Mitochondrial Plasticity Promotes Resistance to Sorafenib and Vulnerability to STAT3 Inhibition in Human Hepatocellular Carcinoma
    Shusil K. Pandit, Giada Sandrini, Jessica Merulla, Valentina Nobili, Xin Wang, Alessia Zangari, Andrea Rinaldi, Dheeraj Shinde, Giuseppina M. Carbone, Carlo V. Catapano
    Cancers.2021; 13(23): 6029.     CrossRef
  • Phosphotyrosine isosteres: past, present and future
    Robert A. Cerulli, Joshua A. Kritzer
    Organic & Biomolecular Chemistry.2020; 18(4): 583.     CrossRef
  • Rewiring Host Signaling: Hepatitis C Virus in Liver Pathogenesis
    Alessia Virzì, Armando Andres Roca Suarez, Thomas F. Baumert, Joachim Lupberger
    Cold Spring Harbor Perspectives in Medicine.2020; 10(1): a037366.     CrossRef
  • Quinazoline Ligands Induce Cancer Cell Death through Selective STAT3 Inhibition and G-Quadruplex Stabilization
    Jan Jamroskovic, Mara Doimo, Karam Chand, Ikenna Obi, Rajendra Kumar, Kristoffer Brännström, Mattias Hedenström, Rabindra Nath Das, Almaz Akhunzianov, Marco Deiana, Kazutoshi Kasho, Sebastian Sulis Sato, Parham L. Pourbozorgi, James E. Mason, Paolo Medini
    Journal of the American Chemical Society.2020; 142(6): 2876.     CrossRef
  • JAK/STAT signaling in hepatocellular carcinoma
    Justin Jit Hin Tang, Dexter Kai Hao Thng, Jhin Jieh Lim, Tan Boon Toh
    Hepatic Oncology.2020;[Epub]     CrossRef
  • Targeting apoptosis in cancer therapy
    Benedito A. Carneiro, Wafik S. El-Deiry
    Nature Reviews Clinical Oncology.2020; 17(7): 395.     CrossRef
  • Targeting acute myeloid leukemia stem cells: Current therapies in development and potential strategies with new dimensions
    Yuxin Tan, Qiuji Wu, Fuling Zhou
    Critical Reviews in Oncology/Hematology.2020; 152: 102993.     CrossRef
  • Manipulation of JAK/STAT Signalling by High-Risk HPVs: Potential Therapeutic Targets for HPV-Associated Malignancies
    Ethan L. Morgan, Andrew Macdonald
    Viruses.2020; 12(9): 977.     CrossRef
  • STAT3 inhibition protects against neuroinflammation and BACE1 upregulation induced by systemic inflammation
    Périne Millot, Carine San, Evangeline Bennana, Baptiste Porte, Nicolas Vignal, Jacques Hugon, Claire Paquet, Benoit Hosten, François Mouton-Liger
    Immunology Letters.2020; 228: 129.     CrossRef
  • STAT3 Inhibitor OPB-51602 Is Cytotoxic to Tumor Cells Through Inhibition of Complex I and ROS Induction
    Lara Brambilla, Tanaya Lahiri, Michael Cammer, David E. Levy
    iScience.2020; 23(12): 101822.     CrossRef
  • Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes
    Chen-Hao Zhang, Ming Li, You-Pei Lin, Qiang Gao
    Current Gene Therapy.2020; 20(2): 84.     CrossRef
  • STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review
    Jiang-Jiang Qin, Li Yan, Jia Zhang, Wei-Dong Zhang
    Journal of Experimental & Clinical Cancer Research.2019;[Epub]     CrossRef
  • Recent Insights Into the Multiple Pathways Driving Non-alcoholic Steatohepatitis-Derived Hepatocellular Carcinoma
    Kazuki Takakura, Tsunekazu Oikawa, Masanori Nakano, Chisato Saeki, Yuichi Torisu, Mikio Kajihara, Masayuki Saruta
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • Direct Targeting Options for STAT3 and STAT5 in Cancer
    Anna Orlova, Christina Wagner, Elvin D. de Araujo, Dávid Bajusz, Heidi A. Neubauer, Marco Herling, Patrick T. Gunning, György M. Keserű, Richard Moriggl
    Cancers.2019; 11(12): 1930.     CrossRef
  • 10,922 View
  • 316 Download
  • 42 Web of Science
  • 42 Crossref
Close layer
Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)
In Hae Park, Seock-Ah Im, Kyung Hae Jung, Joo Hyuk Sohn, Yeon Hee Park, Keun Seok Lee, Sung Hoon Sim, Kyong-Hwa Park, Jee Hyun Kim, Byung Ho Nam, Hee-Jun Kim, Tae-Yong Kim, Kyung-Hun Lee, Sung-Bae Kim, Jin-Hee Ahn, Suee Lee, Jungsil Ro
Cancer Res Treat. 2019;51(1):43-52.   Published online February 14, 2018
DOI: https://doi.org/10.4143/crt.2017.562
AbstractAbstract PDFPubReaderePub
Purpose
We investigated whether irinotecan plus capecitabine improved progression-free survival (PFS) compared with capecitabine alone in patients with human epidermal growth factor 2 (HER2) negative and anthracycline and taxane pretreated metastatic breast cancer (MBC).
Materials and Methods
A total of 221 patients were randomly assigned to irinotecan (80 mg/m2, days 1 and 8) and capecitabine (1,000 mg/m2 twice a day, days 1-14) or capecitabine alone (1,250 mg/m2 twice a day, days 1-14) every 3 weeks. The primary endpoint was PFS.
Results
There was no significant difference in PFS between the combination and monotherapy arm (median, 6.4 months vs. 4.7 months; hazard ratio [HR], 0.84; 95% confidence interval [CI], 0.63 to 1.11; p=0.84). In patients with triple-negative breast cancer (TNBC, n=90), the combination significantly improved PFS (median, 4.7 months vs. 2.5 months; HR, 0.58; 95% CI, 0.37 to 0.91; p=0.02). Objective response rate was numerically higher in the combination arm, though it failed to reach statistical significance (44.4% vs. 33.3%, p=0.30). Overall survival did not differ between arms (median, 20.4 months vs. 24.0 months; p=0.63). While grade 3 or 4 neutropenia was more common in the combination arm (39.6% vs 9.0%), hand-foot syndrome was more often observed in capecitabine arm. Quality of life measurements in global health status was similar. However, patients in the combination arm showed significantly worse symptom scales especially in nausea/vomiting and diarrhea.
Conclusion
Irinotecan plus capecitabine did not prove clinically superior to single-agent capecitabine in anthracycline- and taxane-pretreated HER2 negative MBC patients. Toxicity profiles of the two groups differed but were manageable. The role of added irinotecan in patients with TNBC remains to be elucidated.

Citations

Citations to this article as recorded by  
  • The Survival and Financial Benefit of Investigator-Initiated Trials Conducted by Korean Cancer Study Group
    Bum Jun Kim, Chi Hoon Maeng, Bhumsuk Keam, Young-Hyuck Im, Jungsil Ro, Kyung Hae Jung, Seock-Ah Im, Tae Won Kim, Jae Lyun Lee, Dae Seog Heo, Sang-We Kim, Keunchil Park, Myung-Ju Ahn, Byoung Chul Cho, Hoon-Kyo Kim, Yoon-Koo Kang, Jae Yong Cho, Hwan Jung Yu
    Cancer Research and Treatment.2025; 57(1): 39.     CrossRef
  • Second-Line Treatment Options for Patients with Metastatic Triple-Negative Breast Cancer: A Review of the Clinical Evidence
    José Ángel García-Saenz, Álvaro Rodríguez-Lescure, Josefina Cruz, Joan Albanell, Emilio Alba, Antonio Llombart
    Targeted Oncology.2025; 20(2): 191.     CrossRef
  • Targeting EMSY-mediated methionine metabolism is a potential therapeutic strategy for triple-negative breast cancer
    Cui-Cui Liu, Lie Chen, Yu-Wen Cai, Yu-Fei Chen, Yi-Ming Liu, Yu-Jie Zhou, Zhi-Ming Shao, Ke-Da Yu
    Cell Reports Medicine.2024; 5(2): 101396.     CrossRef
  • Efficacy and safety of nanoparticle albumin‐bound paclitaxel in taxane‐pretreated metastatic breast cancer patients
    Weili Xiong, Ting Xu, Xiao Liu, Lili Zhang, Yuan Yuan
    Cancer.2024; 130(S8): 1488.     CrossRef
  • Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study
    Mengqian Ni, Lijia Zhou, Yongkui Lu, Dachuan Guo, Xiuyue Li, Lixia Li, Lidong Zhang, Meiting Chen, Lulu Zhang, Fei Xu, Zhongyu Yuan, Shusen Wang, Yanxia Shi, Anli Yang, Xin An
    BMC Cancer.2024;[Epub]     CrossRef
  • Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
    Sara A. Hurvitz, Aditya Bardia, Kevin Punie, Kevin Kalinsky, Lisa A. Carey, Hope S. Rugo, Véronique Diéras, See Phan, Rosemary Delaney, Yanni Zhu, Sara M. Tolaney
    npj Breast Cancer.2024;[Epub]     CrossRef
  • A Dual Bispecific Hydrolysis Peptide‐Drug Conjugate Responsive to Micro‐Acidic and Reduction Circumstance Promotes Antitumor Efficacy in Triple‐Negative Breast Cancer
    Tingting Tang, Naiyu Liu, Lingjuan Wang, Kaiyue Zuo, Xinjie Zhu
    ChemBioChem.2024;[Epub]     CrossRef
  • Synergizing Immunotherapy and Antibody–Drug Conjugates: New Horizons in Breast Cancer Therapy
    Antonello Pinto, Chiara Guarini, Marianna Giampaglia, Valeria Sanna, Assunta Melaccio, Laura Lanotte, Anna Natalizia Santoro, Francesca Pini, Antonio Cusmai, Francesco Giuliani, Gennaro Gadaleta-Caldarola, Palma Fedele
    Pharmaceutics.2024; 16(9): 1146.     CrossRef
  • Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors
    Yoichi Naito, Seigo Nakamura, Nobuko Kawaguchi-Sakita, Takanori Ishida, Takahiro Nakayama, Yutaka Yamamoto, Norikazu Masuda, Koji Matsumoto, Takahiro Kogawa, Kazuki Sudo, Akihiko Shimomura, Catherine Lai, Danjie Zhang, Yuki Iwahori, Dianna Gary, Danh Huyn
    International Journal of Clinical Oncology.2024; 29(11): 1684.     CrossRef
  • A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple‐negative breast cancer who received at least two prior treatments
    Binghe Xu, Fei Ma, Tao Wang, Shusen Wang, Zhongsheng Tong, Wei Li, Xinhong Wu, Xiaojia Wang, Tao Sun, Yueyin Pan, Herui Yao, Xian Wang, Ting Luo, Jin Yang, Xiaohua Zeng, Weihong Zhao, Xiuyu Julie Cong, Jiongjie Chen
    International Journal of Cancer.2023; 152(10): 2134.     CrossRef
  • Update on Classic and Novel Approaches in Metastatic Triple-Negative Breast Cancer Treatment: A Comprehensive Review
    Salvatore Greco, Nicolò Fabbri, Riccardo Spaggiari, Alfredo De Giorgi, Fabio Fabbian, Antonio Giovine
    Biomedicines.2023; 11(6): 1772.     CrossRef
  • Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer
    Jiao Xie, SiNi Li, YaMin Li, JianHe Li
    BMC Health Services Research.2023;[Epub]     CrossRef
  • Triple negative breast cancer: second and successive lines of treatment
    Fernando Henao Carrasco, Sara Leal Sánchez
    Revisiones en Cáncer.2023;[Epub]     CrossRef
  • TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer
    Rebecca A Dent, David W Cescon, Thomas Bachelot, Kyung Hae Jung, Zhi-Ming Shao, Shigehira Saji, Tiffany A Traina, Petra Vukovic, Darlington Mapiye, Micah J Maxwell, Peter Schmid, Javier Cortés
    Future Oncology.2023; 19(35): 2349.     CrossRef
  • An integrated analysis of Sacituzumab govitecan in relapsed or refractory metastatic triple-negative breast cancer
    Shao-Xian Cheng, Qiu-Chi Chen, Guo-He Lin, Yan-Hong Han, Bi-Cheng Wang, Yi Dai, Yan-Xia Zhao
    Medicine.2023; 102(30): e34486.     CrossRef
  • Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database
    Wensheng Liu, Qiong Du, Zihan Guo, Xuan Ye, Jiyong Liu
    Frontiers in Pharmacology.2023;[Epub]     CrossRef
  • Effects of Sacituzumab on Breast Cancer: Target Therapy
    Elina Armani Khatibi, Tooba Gholikhani, Balam Jimenez Brito, Nastaran Farshbaf Moghimi
    Biomedical Research Bulletin.2023; 1(4): 141.     CrossRef
  • The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC
    Chris Twelves, Rupert Bartsch, Noa Efrat Ben-Baruch, Simona Borstnar, Luc Dirix, Petra Tesarova, Constanta Timcheva, Lyudmila Zhukova, Xavier Pivot
    Clinical Breast Cancer.2022; 22(3): 223.     CrossRef
  • Quality-of-life methodology in hormone receptor–positive advanced breast cancer: Current tools and perspectives for the future
    Fatima Cardoso, David Cella, Galina Velikova, Victoria Harmer, Eva Schumacher-Wulf, Julie Rihani, Ana Casas, Nadia Harbeck
    Cancer Treatment Reviews.2022; 102: 102321.     CrossRef
  • Comprehensive metabolomics expands precision medicine for triple-negative breast cancer
    Yi Xiao, Ding Ma, Yun-Song Yang, Fan Yang, Jia-Han Ding, Yue Gong, Lin Jiang, Li-Ping Ge, Song-Yang Wu, Qiang Yu, Qing Zhang, François Bertucci, Qiuzhuang Sun, Xin Hu, Da-Qiang Li, Zhi-Ming Shao, Yi-Zhou Jiang
    Cell Research.2022; 32(5): 477.     CrossRef
  • Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival
    F. Miglietta, M. Bottosso, G. Griguolo, M.V. Dieci, V. Guarneri
    ESMO Open.2022; 7(2): 100409.     CrossRef
  • Association of Quality-of-Life Outcomes in Cancer Drug Trials With Survival Outcomes and Drug Class
    Joseph N. Samuel, Christopher M. Booth, Elizabeth Eisenhauer, Michael Brundage, Scott R. Berry, Bishal Gyawali
    JAMA Oncology.2022; 8(6): 879.     CrossRef
  • Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
    Joyce O’Shaughnessy, Adam Brufsky, Hope S. Rugo, Sara M. Tolaney, Kevin Punie, Sagar Sardesai, Erika Hamilton, Delphine Loirat, Tiffany Traina, Roberto Leon-Ferre, Sara A. Hurvitz, Kevin Kalinsky, Aditya Bardia, Stephanie Henry, Ingrid Mayer, Yanni Zhu, S
    Breast Cancer Research and Treatment.2022; 195(2): 127.     CrossRef
  • Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis
    Lisa A. Carey, Delphine Loirat, Kevin Punie, Aditya Bardia, Véronique Diéras, Florence Dalenc, Jennifer R. Diamond, Christel Fontaine, Grace Wang, Hope S. Rugo, Sara A. Hurvitz, Kevin Kalinsky, Joyce O’Shaughnessy, Sibylle Loibl, Luca Gianni, Martine Picc
    npj Breast Cancer.2022;[Epub]     CrossRef
  • Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer
    Hope S. Rugo, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Aditya Bardia, Sara A. Hurvitz, Joyce O’Shaughnessy, Javier Cortés, Véronique Diéras, Lisa A. Carey, Luca Gianni, Martine J. Piccart, Sibylle Loibl, David M. Goldenberg, Quan Hong, Martin Olivo,
    npj Breast Cancer.2022;[Epub]     CrossRef
  • Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial
    Dou-Dou Li, Zhong-hua Tao, Bi-Yun Wang, Lei-Ping Wang, Jun Cao, Xi-Chun Hu, Jian Zhang
    npj Breast Cancer.2022;[Epub]     CrossRef
  • Combination treatment of radiofrequency ablation and peptide neoantigen vaccination: Promising modality for future cancer immunotherapy
    Jiawei Shou, Fan Mo, Shanshan Zhang, Lantian Lu, Ning Han, Liang Liu, Min Qiu, Hongseng Li, Weidong Han, Dongying Ma, Xiaojie Guo, Qianpeng Guo, Qinxue Huang, Xiaomeng Zhang, Shengli Ye, Hongming Pan, Shuqing Chen, Yong Fang
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer
    Min Yan, Peng Yuan, Quchang Ouyang, Ying Cheng, Guohui Han, Dewei Wang, Li Ran, Tao Sun, Da Zhao, Yuju Bai, Shun’e Yang, Xiaojia Wang, Rong Wu, Xiaohua Zeng, Herui Yao, Xuening Ji, Jun Jiang, Xiaohua Hu, Haifeng Lin, Liping Zheng, Zhitu Zhu, Wei Ge, Junla
    Therapeutic Advances in Medical Oncology.2022;[Epub]     CrossRef
  • Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase
    Jasgit C. Sachdev, Pamela Munster, Donald W. Northfelt, Hyo Sook Han, Cynthia Ma, Fiona Maxwell, Tiffany Wang, Bruce Belanger, Bin Zhang, Yan Moore, Arunthathi Thiagalingam, Carey Anders
    Breast Cancer Research and Treatment.2021; 185(3): 759.     CrossRef
  • Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
    Aditya Bardia, Sara A. Hurvitz, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam Brufsky, Sagar D. Sardesai, Kevin Kalinsky, Amelia B. Zelnak, Robert Weaver, Tiffany Traina, Florence Dalenc, Philippe Aftimos, Filipa Lynce, Sami Diab,
    New England Journal of Medicine.2021; 384(16): 1529.     CrossRef
  • Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study
    Linda T. Vahdat, Peter Schmid, Andres Forero-Torres, Kimberly Blackwell, Melinda L. Telli, Michelle Melisko, Volker Möbus, Javier Cortes, Alberto J. Montero, Cynthia Ma, Rita Nanda, Gail S. Wright, Yi He, Thomas Hawthorne, Rebecca G. Bagley, Abdel-Baset H
    npj Breast Cancer.2021;[Epub]     CrossRef
  • Occult triple negative male breast cancer. The usefulness of molecular platforms. A case report
    Angelats L, Estival A, Martinez-Cardús A, Musulen E, Margelí M
    Current Problems in Cancer: Case Reports.2021; : 100097.     CrossRef
  • A Retrospective Analysis of the Effect of Irinotecan-Based Regimens in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
    Jiaojiao Suo, Xiaorong Zhong, Ping He, Hong Zheng, Tinglun Tian, Xi Yan, Ting Luo
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies
    Ellen Cusano, Chelsea Wong, Eddy Taguedong, Marcus Vaska, Tasnima Abedin, Nancy Nixon, Safiya Karim, Patricia Tang, Daniel Y. C. Heng, Doreen Ezeife
    Current Oncology.2021; 28(6): 4894.     CrossRef
  • High Antitumor Activity of the Dual Topoisomerase Inhibitor P8-D6 in Breast Cancer
    Inken Flörkemeier, Tamara N. Steinhauer, Nina Hedemann, Jörg Paul Weimer, Christoph Rogmans, Marion T. van Mackelenbergh, Nicolai Maass, Bernd Clement, Dirk O. Bauerschlag
    Cancers.2021; 14(1): 2.     CrossRef
  • Clinical outcomes of breast cancer patients treated in phase I clinical trials at University of Colorado Cancer Center
    Jennifer A. Weiss, Andrew Nicklawsky, Jodi A. Kagihara, Dexiang Gao, Christine Fisher, Anthony Elias, Virginia F. Borges, Peter Kabos, Sarah L. Davis, Stephen Leong, Sue Gail Eckhardt, Jennifer R. Diamond
    Cancer Medicine.2020; 9(23): 8801.     CrossRef
  • Chemotherapy Options beyond the First Line in HER-Negative Metastatic Breast Cancer
    Vito Lorusso, Agnese Latorre, Francesco Giotta, Ozkan Kanat
    Journal of Oncology.2020; 2020: 1.     CrossRef
  • Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
    Aditya Bardia, Ingrid A. Mayer, Linda T. Vahdat, Sara M. Tolaney, Steven J. Isakoff, Jennifer R. Diamond, Joyce O’Shaughnessy, Rebecca L. Moroose, Alessandro D. Santin, Vandana G. Abramson, Nikita C. Shah, Hope S. Rugo, David M. Goldenberg, Ala M. Sweidan
    New England Journal of Medicine.2019; 380(8): 741.     CrossRef
  • An open label phase 1 study evaluation safety, tolerability, and maximum tolerated dose of oral administration of irinotecan in combination with capecitabine
    I. Kümler, R. L. Eefsen, Peter Grundtvig Sørensen, S. Theile, A. Fullerton, P. G. Nielsen, Benny Vittrup Jensen, D. L. Nielsen
    Cancer Chemotherapy and Pharmacology.2019; 84(2): 441.     CrossRef
  • Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy
    Burak Yasin Aktas, Gurkan Guner, Deniz Can Guven, Cagatay Arslan, Omer Dizdar
    Expert Review of Anticancer Therapy.2019; 19(7): 589.     CrossRef
  • Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer
    Jennifer Weiss, Ashley Glode, Wells A. Messersmith, Jennifer Diamond
    Expert Review of Anticancer Therapy.2019; 19(8): 673.     CrossRef
  • The role of capecitabine and eribulin in the treatment of metastatic HER2-negative metastatic breast cancer
    I V Kolyadina, I V Poddubnaya
    Journal of Modern Oncology.2018; 20(3): 26.     CrossRef
  • 11,080 View
  • 455 Download
  • 38 Web of Science
  • 42 Crossref
Close layer
Negative Conversion of Progesterone Receptor Status after Primary Systemic Therapy Is Associated with Poor Clinical Outcome in Patients with Breast Cancer
Soomin Ahn, Hyun Jeong Kim, Milim Kim, Yul Ri Chung, Eunyoung Kang, Eun-Kyu Kim, Se Hyun Kim, Yu Jung Kim, Jee Hyun Kim, In Ah Kim, So Yeon Park
Cancer Res Treat. 2018;50(4):1418-1432.   Published online January 24, 2018
DOI: https://doi.org/10.4143/crt.2017.552
AbstractAbstract PDFPubReaderePub
Purpose
Alteration of biomarker status after primary systemic therapy (PST) is occasionally found in breast cancer. This study was conducted to clarify the clinical implications of change of biomarker status in breast cancer patients treated with PST.
Materials and Methods
The pre-chemotherapeutic biopsy and post-chemotherapeutic resection specimens of 442 breast cancer patients who had residual disease after PST were included in this study. The association between changes of biomarker status after PST and clinicopathologic features of tumors, and survival of the patients, were analyzed.
Results
Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status changed after PST in 18 (4.1%), 80 (18.1%), and 15 (3.4%) patients,respectively. ER and PR mainly underwent positive to negative conversion,whereas HER2 status underwent negative to positive conversion. Negative conversion of ER and PR status after PST was associated with reduced disease-free survival. Moreover, a decline in the Allred score for PR in post-PST specimens was significantly associated with poor clinical outcome of the patients. HER2 change did not have prognostic significance. In multivariate analyses, negative PR status after PST was found to be an independent adverse prognostic factor in the whole patient group, in the adjuvant endocrine therapy-treated subgroup, and also in pre-PST PR positive subgroup.
Conclusion
ER and HER2 status changed little after PST, whereas PR status changed significantly. In particular, negative conversion of PR status was revealed as a poor prognostic indicator, suggesting that re-evaluation of basic biomarkers is mandatory in breast cancer after PST for proper management and prognostication of patients.

Citations

Citations to this article as recorded by  
  • Impact of hormone receptor and HER2 conversions on survival after neoadjuvant chemotherapy in breast cancer patients
    Ran Feng, Lihui Pan, Yarong Yao, Jinnan Gao, Xiaojun Zhang
    Oncology and Translational Medicine.2025; 11(2): 73.     CrossRef
  • Changing the phenotype of breast cancer in the process treatment: literature review
    M. S. Shvedsky, R. I. Tamrazov, T. P. Shevlyukova, L. A. Bakhova
    Surgery and Oncology.2024; 13(4): 50.     CrossRef
  • HER2-low breast cancer and response to neoadjuvant chemotherapy: a population-based cohort study
    Ximena Baez-Navarro, Mieke R. van Bockstal, Agnes Jager, Carolien H.M. van Deurzen
    Pathology.2024; 56(3): 334.     CrossRef
  • NGS mutational status on first diagnostic tissue, liquid biopsy and mastectomy in G2–G3 breast cancer
    Carmen Maria Ardeleanu, Maria Victoria Olinca , Cristian Gabriel Viişoreanu , Horaţiu Alin Mureşan , Adriana Tecuceanu-Vulpe , Georgiana Manole , Iulia Elena Gune , Bianca Gălăţeanu , Andreea-Corina Ilie-Petrov
    Romanian Journal of Morphology and Embryology.2024; 65(2): 195.     CrossRef
  • Applicability of Quantum Dots in Breast Cancer Diagnostic and Therapeutic Modalities—A State-of-the-Art Review
    Dominika Kunachowicz, Karolina Kłosowska, Natalia Sobczak, Marta Kepinska
    Nanomaterials.2024; 14(17): 1424.     CrossRef
  • Progesterone and progesterone receptors in breast cancer: past, present, and future
    M. V. Rodionova, V. V. Rodionov, V. V. Kometova, A. A. Smetnik, I. V. Kolyadina, O. V. Burmenskaya, V. K. Bozhenko, Yu. V. Bikeev, L. M. Mikhaleva, L. A. Ashrafyan
    Tumors of female reproductive system.2024; 20(4): 70.     CrossRef
  • Establishment and evaluation of digital PCR methods for HER2 copy number variation in breast cancer
    Xia Wang, Dechun Xing, Zheng Liu, Yujing Zhang, Bo Cheng, Suozhu Sun, Qingtao Wang, Lianhua Dong
    Analytical and Bioanalytical Chemistry.2023; 415(4): 725.     CrossRef
  • Clinical significance and prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients
    Yang He, Jing Zhang, Hui Chen, Ying Zhou, Liping Hong, Yue Ma, Nannan Chen, Weipeng Zhao, Zhongsheng Tong
    Frontiers in Surgery.2023;[Epub]     CrossRef
  • Conversion of ER and HER2 Status After Neoadjuvant Therapy in Chinese Breast Cancer Patients
    Jiaqi Bo, Baohua Yu, Rui Bi, Xiaoli Xu, Yufan Cheng, Xiaoyu Tu, Qianming Bai, Wentao Yang, Ruohong Shui
    Clinical Breast Cancer.2023; 23(4): 436.     CrossRef
  • Récepteur du facteur de croissance épidermique HER2, tests utilisés pour rechercher son amplification dans le cancer du sein : principes et limites
    Imane Eliahiai, Mohammed Eljiar, Sanae Chaib, Jinane KHarmoum, Mariame Chraïbi
    Bulletin du Cancer.2023; 110(12): 1301.     CrossRef
  • HER2 changes to positive after neoadjuvant chemotherapy in breast cancer: A case report and literature review
    Luo Wang, Qi Jiang, Meng-Ye He, Peng Shen
    World Journal of Clinical Cases.2022; 10(1): 260.     CrossRef
  • Experience with olaparib in a patient with luminal HER2-positive metastatic breast cancer
    L. V. Bolotina, A. L. Kornietskaya, A. A. Kachmazov, N. S. Prizova, A. A. Paichadze, T. V. Ustinova, T. I. Deshkina, S. F. Evdokimova
    Meditsinskiy sovet = Medical Council.2022; (9): 179.     CrossRef
  • Machine learning on MRI radiomic features: identification of molecular subtype alteration in breast cancer after neoadjuvant therapy
    Hai-Qing Liu, Si-Ying Lin, Yi-Dong Song, Si-Yao Mai, Yue-dong Yang, Kai Chen, Zhuo Wu, Hui-Ying Zhao
    European Radiology.2022; 33(4): 2965.     CrossRef
  • Biomarker Alteration after Neoadjuvant Endocrine Therapy or Chemotherapy in Estrogen Receptor-Positive Breast Cancer
    Mengping Long, Chong You, Qianqian Song, Lina Hu, Zhaorong Guo, Qian Yao, Wei Hou, Wei Sun, Baosheng Liang, Xiao-Hua Zhou, Yiqiang Liu, Taobo Hu
    Life.2022; 13(1): 74.     CrossRef
  • The impact of progesterone receptor negativity on oncological outcomes in oestrogen-receptor-positive breast cancer
    M G Davey, É J Ryan, P J Folan, N O’Halloran, M R Boland, M K Barry, K J Sweeney, C M Malone, R J McLaughlin, M J Kerin, A J Lowery
    BJS Open.2021;[Epub]     CrossRef
  • Prognostic implications of regression of metastatic axillary lymph nodes after neoadjuvant chemotherapy in patients with breast cancer
    Yul Ri Chung, Ji Won Woo, Soomin Ahn, Eunyoung Kang, Eun-Kyu Kim, Mijung Jang, Sun Mi Kim, Se Hyun Kim, Jee Hyun Kim, So Yeon Park
    Scientific Reports.2021;[Epub]     CrossRef
  • Enriched transcriptome analysis of laser capture microdissected populations of single cells to investigate intracellular heterogeneity in immunostained FFPE sections
    Sarah M. Hammoudeh, Arabella M. Hammoudeh, Thenmozhi Venkatachalam, Surendra Rawat, Manju N. Jayakumar, Mohamed Rahmani, Rifat Hamoudi
    Computational and Structural Biotechnology Journal.2021; 19: 5198.     CrossRef
  • Lost but Not Least—Novel Insights into Progesterone Receptor Loss in Estrogen Receptor-Positive Breast Cancer
    Michał Kunc, Marta Popęda, Wojciech Biernat, Elżbieta Senkus
    Cancers.2021; 13(19): 4755.     CrossRef
  • Biomarkers Changes after Neoadjuvant Chemotherapy in Breast Cancer: A Seven-Year Single Institution Experience
    Saverio Coiro, Elisa Gasparini, Giuseppe Falco, Giacomo Santandrea, Moira Foroni, Giulia Besutti, Valentina Iotti, Roberto Di Cicilia, Monica Foroni, Simone Mele, Guglielmo Ferrari, Giancarlo Bisagni, Moira Ragazzi
    Diagnostics.2021; 11(12): 2249.     CrossRef
  • HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation
    Soomin Ahn, Ji Won Woo, Kyoungyul Lee, So Yeon Park
    Journal of Pathology and Translational Medicine.2020; 54(1): 34.     CrossRef
  • Effect of neoadjuvant therapy on breast cancer biomarker profile
    Laura Rey-Vargas, Juan Carlos Mejía-Henao, María Carolina Sanabria-Salas, Silvia J. Serrano-Gomez
    BMC Cancer.2020;[Epub]     CrossRef
  • Changes in Biomarker Status in Metastatic Breast Cancer and Their Prognostic Value
    Ji Won Woo, Yul Ri Chung, Soomin Ahn, Eunyoung Kang, Eun-Kyu Kim, Se Hyun Kim, Jee Hyun Kim, In Ah Kim, So Yeon Park
    Journal of Breast Cancer.2019; 22(3): 439.     CrossRef
  • 10,656 View
  • 199 Download
  • 19 Web of Science
  • 22 Crossref
Close layer
A Novel Prognostic Nomogram for Predicting Risks of Distant Failure in Patients with Invasive Breast Cancer Following Postoperative Adjuvant Radiotherapy
Yu Jin Lim, Sea-Won Lee, Noorie Choi, Jeanny Kwon, Keun-Yong Eom, Eunyoung Kang, Eun-Kyu Kim, Jee Hyun Kim, Yu Jung Kim, Se Hyun Kim, So Yeon Park, In Ah Kim
Cancer Res Treat. 2018;50(4):1140-1148.   Published online December 7, 2017
DOI: https://doi.org/10.4143/crt.2017.508
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to identify predictors for distant metastatic behavior and build a related prognostic nomogram in breast cancer.
Materials and Methods
A total of 1,181 patients with non-metastatic breast cancer between 2003 and 2011 were analyzed. To predict the probability of distant metastasis, a nomogram was constructed based on prognostic factors identified using a Cox proportional hazards model.
Results
The 7-year overall survival and 5-year post-progression survival of locoregional versus distant recurrence groups were 67.6% versus 39.1% (p=0.027) and 54.2% versus 33.5% (p=0.043), respectively. Patients who developed distant metastasis showed early and late mortality risk peaks within 3 and after 5 years of follow-up, respectively, but a broad and low risk increment was observed in other patients with locoregional relapse. In multivariate analysis of distant metastasis-free interval, age (≥ 45 years vs. < 45 years), molecular subtypes (luminal A vs. luminal B, human epidermal growth receptor 2, and triple negative), T category (T1 vs. T2-3 and T4), and N category (N0 vs. N1 and N2-3) were independently associated (p < 0.05 for all). Regarding the significant factors, a well-validated nomogram was established (concordance index, 0.812). The risk score level of patients with initial brain failure was higher than those of non-brain sites (p=0.029).
Conclusion
The nomogram could be useful for predicting the individual probability of distant recurrence in breast cancer. In high-risk patients based on the risk scores, more aggressive systemic therapy and closer surveillance for metastatic failure should be considered.

Citations

Citations to this article as recorded by  
  • Predicting Patterns of Distant Metastasis in Breast Cancer Patients following Local Regional Therapy Using Machine Learning
    Audrey Shiner, Alex Kiss, Khadijeh Saednia, Katarzyna J. Jerzak, Sonal Gandhi, Fang-I Lu, Urban Emmenegger, Lauren Fleshner, Andrew Lagree, Marie Angeli Alera, Mateusz Bielecki, Ethan Law, Brianna Law, Dylan Kam, Jonathan Klein, Christopher J. Pinard, Ale
    Genes.2023; 14(9): 1768.     CrossRef
  • Nomograms for Predicting Specific Distant Metastatic Sites and Overall Survival of Breast Invasive Ductal Carcinoma Patients After Surgery: A Large Population-Based Study
    Yuqian Feng, Yiting Zhang, Yuying Xiang, Kaibo Guo, Huimin Jin, Shanming Ruan, Zhuoya Guan
    Frontiers in Surgery.2022;[Epub]     CrossRef
  • Cost-effectiveness of postmastectomy hypofractionated radiation therapy vs conventional fractionated radiation therapy for high-risk breast cancer
    Jing Yang, Shu-Nan Qi, Hui Fang, Yong-Wen Song, Jing Jin, Yue-Ping Liu, Wei-Hu Wang, Yong Yang, Yu Tang, Hua Ren, Bo Chen, Ning-Ning Lu, Yuan Tang, Ning Li, Hao Jing, Shu-Lian Wang, Ye-Xiong Li
    The Breast.2021; 58: 72.     CrossRef
  • Prediction of distant metastatic recurrence by tumor-infiltrating lymphocytes in hormone receptor-positive breast cancer
    Koji Takada, Shinichiro Kashiwagi, Yuka Asano, Wataru Goto, Rika Kouhashi, Akimichi Yabumoto, Sae Ishihara, Tamami Morisaki, Masatsune Shibutani, Hiroaki Tanaka, Kosei Hirakawa, Masaichi Ohira
    BMC Women's Health.2021;[Epub]     CrossRef
  • Nomogram for the personalisation of radiotherapy treatments in breast cancer patients
    Inmaculada Beato Tortajada, Carlos Ferrer Albiach, Virginia Morillo Macias
    The Breast.2021; 60: 255.     CrossRef
  • Prognostic Factors and Nomograms to Predict Overall and Cancer-Specific Survival for Children with Wilms’ Tumor
    Fucai Tang, Hanbin Zhang, Zechao Lu, Jiamin Wang, Chengwu He, Zhaohui He
    Disease Markers.2019; 2019: 1.     CrossRef
  • Score for the Survival Probability in Metastasis Breast Cancer: A Nomogram-Based Risk Assessment Model
    Zhenchong Xiong, Guangzheng Deng, Xinjian Huang, Xing Li, Xinhua Xie, Jin Wang, Zeyu Shuang, Xi Wang
    Cancer Research and Treatment.2018; 50(4): 1260.     CrossRef
  • 9,452 View
  • 233 Download
  • 11 Web of Science
  • 7 Crossref
Close layer
Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
Tae Min Kim, Keun-Wook Lee, Do-Youn Oh, Jong-Seok Lee, Seock-Ah Im, Dong-Wan Kim, Sae-Won Han, Yu Jung Kim, Tae-You Kim, Jee Hyun Kim, Hyesun Han, Woo Ho Kim, Yung-Jue Bang
Cancer Res Treat. 2018;50(3):835-842.   Published online August 29, 2017
DOI: https://doi.org/10.4143/crt.2017.303
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Poziotinib, a pan-human epidermal growth factor receptor 2 (HER) tyrosine kinase inhibitor, has shown potent activity againstwild type of epidermal growth factorreceptor(EGFR) family kinases including EGFR, HER2, and HER4 and EGFR-mutant cells in vitro. Two phase I studies were conducted to determine the maximum tolerated dose (MTD), pharmacokinetics, safety, and antitumor activity against advanced solid tumors.
Materials and Methods
Standard 3+3 dose escalation scheme using two different dosing schedules were studied: once daily, 14-day on, and 7-day off (intermittent schedule); and once daily continuous dosing with food effect. Additional patients were enrolled in an expansion cohort.
Results
A total of 75 patients were enrolled in the two studies. The most common drug-related treatment-emergent adverse eventswere diarrhea,rash, stomatitis, pruritus, and anorexia. Doselimiting toxicities were grade 3 diarrhea in the intermittent schedule and grade 3 anorexia and diarrhea in the continuous dosing schedule. The MTDs were determined as 24 mg/day in the intermittent dosing schedule and 18 mg/day in the continuous dosing schedule. Eight (16%) and 24 (47%) of 51 evaluable patients in the intermittent schedule achieved partial response (PR) and stable disease (SD), respectively. Four (21%) and six (32%) of 19 evaluable patients in continuous dosing schedule achieved PR and SD, respectively. Patients with PR (n=7) or SD ≥ 12 weeks (n=7) had HER2 amplification (n=7; breast cancer, 5; and stomach cancer, 2) and EGFR amplification (n=1, squamous cell lung cancer).
Conclusion
Poziotinib was safe and well tolerated in patients with advanced solid tumors. It showed an encouraging activity against EGFR-mutant and HER2-amplified cancers.

Citations

Citations to this article as recorded by  
  • The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancer
    Barbara Melosky, Rosalyn A. Juergens, Shantanu Banerji, Adrian Sacher, Paul Wheatley-Price, Stephanie Snow, Ming-Sound Tsao, Natasha B. Leighl, Ilidio Martins, Parneet Cheema, Geoffrey Liu, Quincy S. C. Chu
    Therapeutic Advances in Medical Oncology.2025;[Epub]     CrossRef
  • Cellular polarity pilots breast cancer progression and immunosuppression
    Jie Huang, Shufeng Luo, Juan Shen, Maya Lee, Rachel Chen, Shenglin Ma, Lun-Quan Sun, Jian Jian Li
    Oncogene.2025; 44(12): 783.     CrossRef
  • The Brain-Penetrant Pan-ErbB Inhibitor Poziotinib Effectively Targets HER2+ Breast Cancer Brain Metastases
    Danyyl Ippolitov, Yi-Han Lin, Jeremy Spence, Aleksandra Glogowska, Thatchawan Thanasupawat, Jason Beiko, Marc R. Del Bigio, Xin Xu, Amy Q. Wang, Darian Williams, Raul Calvo, Abhijeet Kapoor, Juan J. Marugan, Mark J. Henderson, Thomas Klonisch, Sabine Homb
    Cancer Research.2025; 85(8): 1514.     CrossRef
  • Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion
    Akira Hamada, Kenichi Suda, Masaya Nishino, Keiko Obata, Hana Oiki, Tomoyo Fukami, Shota Fukuda, Toshio Fujino, Shuta Ohara, Takamasa Koga, Masato Chiba, Masaki Shimoji, Masaoki Ito, Toshiki Takemoto, Junichi Soh, Yasuhiro Tsutani, Tetsuya Mitsudomi
    Journal of Thoracic Oncology.2024; 19(1): 71.     CrossRef
  • Poziotinib treatment in patients with HER2-positive advanced breast cancer who have received prior anti-HER2 regimens
    Azadeh Nasrazadani, Juan Luis Gomez Marti, Kate Lathrop, Alvaro Restrepo, Szu-Yun Leu, Gajanan Bhat, Adam Brufsky
    Breast Cancer Research and Treatment.2024; 205(1): 29.     CrossRef
  • HER2-targeted therapies beyond breast cancer — an update
    Jeesun Yoon, Do-Youn Oh
    Nature Reviews Clinical Oncology.2024; 21(9): 675.     CrossRef
  • Emerging Targeted Therapies for HER2-Positive Breast Cancer
    María Florencia Mercogliano, Sofía Bruni, Florencia Luciana Mauro, Roxana Schillaci
    Cancers.2023; 15(7): 1987.     CrossRef
  • Inhibitory effect of Schisandrin on the pharmacokinetics of poziotinib in vivo and in vitro by UPLC‐MS/MS
    Shuanghu Wang, Mengming Xia, Yu Wang, Zebei Lu, Peiwu Geng, Dapeng Dai, Yunfang Zhou, Qingjun Wu
    Thoracic Cancer.2023; 14(14): 1276.     CrossRef
  • Neratinib for HER2-positive breast cancer with an overlooked option
    Liting Guo, Weiwei Shao, Chenfei Zhou, Hui Yang, Liu Yang, Qu Cai, Junqing Wang, Yan Shi, Lei Huang, Jun Zhang
    Molecular Medicine.2023;[Epub]     CrossRef
  • Clinical Relevance of Patient-Derived Organoid of Surgically Resected Lung Cancer as an In Vitro Model for Biomarker and Drug Testing
    Takamasa Koga, Junichi Soh, Akira Hamada, Yuki Miyano, Toshio Fujino, Keiko Obata, Shuta Ohara, Masaya Nishino, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Kenichi Suda, Kazuko Sakai, Hidenori Sato, Tetsuya Mitsudomi
    JTO Clinical and Research Reports.2023; 4(9): 100554.     CrossRef
  • Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer
    Arnaldo Marín, Abdullah Al Mamun, Hima Patel, Hiroaki Akamatsu, Dan Ye, Dhivya R. Sudhan, Lisa Eli, Katherine Marcelain, Benjamin P. Brown, Jens Meiler, Carlos L. Arteaga, Ariella B. Hanker
    Cancer Research.2023; 83(18): 3145.     CrossRef
  • In Silico and In Vitro Exploration of Poziotinib and Olmutinib Synergy in Lung Cancer: Role of hsa-miR-7-5p in Regulating Apoptotic Pathway Marker Genes
    Salman Alamery, Anfal AlAjmi, Tanveer A. Wani, Seema Zargar
    Medicina.2023; 59(11): 1923.     CrossRef
  • Unlocking New Avenues in Breast Cancer Treatment: The Synergy of Kinase Inhibitors and Immunotherapy
    María José Bravo, Antonio Manuel Burgos-Molina, Marilina García-Aranda, Maximino Redondo, Teresa Téllez
    Cancers.2023; 15(23): 5499.     CrossRef
  • Novel HER-2 Targeted Therapies in Breast Cancer
    Catarina Lopes Fernandes, Diogo J. Silva, Alexandra Mesquita
    Cancers.2023; 16(1): 87.     CrossRef
  • Trastuzumab Deruxtecan for HER2+ Advanced Breast Cancer
    Jiyun Lee, Yeon Hee Park
    Future Oncology.2022; 18(1): 7.     CrossRef
  • Poziotinib in Non–Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial
    Xiuning Le, Robin Cornelissen, Marina Garassino, Jeffrey M. Clarke, Nishan Tchekmedyian, Jonathan W. Goldman, Szu-Yun Leu, Gajanan Bhat, Francois Lebel, John V. Heymach, Mark A. Socinski
    Journal of Clinical Oncology.2022; 40(7): 710.     CrossRef
  • HER2-Altered Non-Small Cell Lung Cancer: Biology, Clinicopathologic Features, and Emerging Therapies
    Xin Yu, Xianxiu Ji, Chunxia Su
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity
    Yasir Y. Elamin, Jacqulyne P. Robichaux, Brett W. Carter, Mehmet Altan, Hai Tran, Don L. Gibbons, Simon Heeke, Frank V. Fossella, Vincent K. Lam, Xiuning Le, Marcelo V. Negrao, Monique B. Nilsson, Anisha Patel, R.S.K. Vijayan, Jason B. Cross, Jianjun Zhan
    Cancer Cell.2022; 40(7): 754.     CrossRef
  • Tailoring antiHer2 treatment strategies in breast cancer and beyond
    Palma Fedele, Valeria Sanna, Anna Natalizia Santoro, Maria Laura Iaia, Alessandro Fancellu
    Current Problems in Cancer.2022; 46(5): 100892.     CrossRef
  • HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives
    Weiling Li, Xiaoling Zhang, Yunyi Du, Ying Zhang, Jing Lu, Wenqing Hu, Jun Zhao
    Biomarker Research.2022;[Epub]     CrossRef
  • Deciphering the Impact of HER2 Alterations on Non-Small-Cell Lung Cancer: From Biological Mechanisms to Therapeutic Approaches
    Christophe Bontoux, Jonathan Benzaquen, Véronique Hofman, Simon Heeke, Paul Hannetel, Pierre Capela-Brosseau-Laborde, Charles-Hugo Marquette, Marius Ilié, Paul Hofman
    Journal of Personalized Medicine.2022; 12(10): 1651.     CrossRef
  • An ultra-performance LC–MS/MS method for determination of JRF103 in human plasma: application in first in-patient study
    Ying Jin, Xiangjie Di, Lisha Fu, Mengyu Zhang, Neng Qiu, Runhan Liu, Fangqun Li, Xiaohui Qi, Xiaoxu Wang, Yongsheng Wang, Zhenlei Wang
    Bioanalysis.2022; 14(17): 1165.     CrossRef
  • Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake
    Alessandro De Toma, Giuseppe Lo Russo, Diego Signorelli, Filippo Pagani, Giovanni Randon, Giulia Galli, Arsela Prelaj, Roberto Ferrara, Claudia Proto, Monica Ganzinelli, Nicoletta Zilembo, Filippo de Braud, Marina Chiara Garassino
    Critical Reviews in Oncology/Hematology.2021; 160: 103299.     CrossRef
  • Effects of dacomitinib on the pharmacokinetics of poziotinib in vivo and in vitro
    Weiping Ji, Jiquan Shen, Bo Wang, Feifei Chen, Deru Meng, Shuanghu Wang, Dapeng Dai, Yunfang Zhou, Changxiong Wang, Quan Zhou
    Pharmaceutical Biology.2021; 59(1): 455.     CrossRef
  • Treating Advanced Unresectable or Metastatic HER2-Positive Breast Cancer: A Spotlight on Tucatinib
    Lara Ulrich, Alicia FC Okines
    Breast Cancer: Targets and Therapy.2021; Volume 13: 361.     CrossRef
  • Current therapeutic options for gastric adenocarcinoma
    C.R. Akshatha, Smitha Bhat, R. Sindhu, Dharini Shashank, Sarana Rose Sommano, Wanaporn Tapingkae, Ratchadawan Cheewangkoon, Shashanka K. Prasad
    Saudi Journal of Biological Sciences.2021; 28(9): 5371.     CrossRef
  • The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer
    Barbara Melosky, Paul Wheatley-Price, Rosalyn A. Juergens, Adrian Sacher, Natasha B. Leighl, Ming-Sound Tsao, Parneet Cheema, Stephanie Snow, Geoffrey Liu, Paul B. Card, Quincy Chu
    Lung Cancer.2021; 160: 136.     CrossRef
  • Pathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer
    Chia-Jung Li, Yen-Dun Tony Tzeng, Yi-Han Chiu, Hung-Yu Lin, Ming-Feng Hou, Pei-Yi Chu
    Cancers.2021; 13(12): 2978.     CrossRef
  • Next‐Generation Kinase Inhibitors Targeting Specific Biomarkers in Non‐Small Cell Lung Cancer (NSCLC): A Recent Overview
    Debasis Das, Jingbing Wang, Jian Hong
    ChemMedChem.2021; 16(16): 2459.     CrossRef
  • Discovery of first-in-class imidazothiazole-based potent and selective ErbB4 (HER4) kinase inhibitors
    Seyed-Omar Zaraei, Rawan M. Sbenati, Nour N. Alach, Hanan S. Anbar, Randa El-Gamal, Hamadeh Tarazi, Mahmoud K. Shehata, Mohammed S. Abdel-Maksoud, Chang-Hyun Oh, Mohammed I. El-Gamal
    European Journal of Medicinal Chemistry.2021; 224: 113674.     CrossRef
  • Breast Cancer Treatments: Updates and New Challenges
    Anna Burguin, Caroline Diorio, Francine Durocher
    Journal of Personalized Medicine.2021; 11(8): 808.     CrossRef
  • Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations
    M. Riudavets, I. Sullivan, P. Abdayem, D. Planchard
    ESMO Open.2021; 6(5): 100260.     CrossRef
  • A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
    Ji Hyun Lee, Seong Gu Heo, Beung‐Chul Ahn, Min Hee Hong, Byoung Chul Cho, Sun Min Lim, Hye Ryun Kim
    Cancer Medicine.2021; 10(20): 7012.     CrossRef
  • In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial
    Akira Hamada, Kenichi Suda, Takamasa Koga, Toshio Fujino, Masaya Nishino, Shuta Ohara, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Junichi Soh, Tetsuro Uchida, Tetsuya Mitsudomi
    Lung Cancer.2021; 162: 79.     CrossRef
  • HER2 Aberrations in Non-Small Cell Lung Cancer: From Pathophysiology to Targeted Therapy
    Ioannis A. Vathiotis, Andriani Charpidou, Niki Gavrielatou, Konstantinos N. Syrigos
    Pharmaceuticals.2021; 14(12): 1300.     CrossRef
  • Conformational Landscapes of HER2 Exon 20 Insertions Explain Their Sensitivity to Kinase Inhibitors in Lung Adenocarcinoma
    Shen Zhao, Wenfeng Fang, Hui Pan, Yunpeng Yang, Ying Liang, Lin Yang, Xiaorong Dong, Jianhua Zhan, Kai Wang, Li Zhang
    Journal of Thoracic Oncology.2020; 15(6): 962.     CrossRef
  • Drug resistance to targeted therapeutic strategies in non-small cell lung cancer
    Wen-juan Liu, Yue Du, Ru Wen, Ming Yang, Jian Xu
    Pharmacology & Therapeutics.2020; 206: 107438.     CrossRef
  • Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC
    Iosune Baraibar, Laura Mezquita, Ignacio Gil-Bazo, David Planchard
    Critical Reviews in Oncology/Hematology.2020; 148: 102906.     CrossRef
  • Mutation Variants and Co-Mutations as Genomic Modifiers of Response to Afatinib in HER2-Mutant Lung Adenocarcinoma
    Wenfeng Fang, Shen Zhao, Ying Liang, Yunpeng Yang, Lin Yang, Xiaorong Dong, Li Zhang, Yong Tang, Shoufeng Wang, Yang Yang, Xiaoyan Ma, Minghui Wang, Wenjing Wang, Songhui Zhao, Kai Wang, Song Gao, Li Zhang
    The Oncologist.2020; 25(3): e545.     CrossRef
  • Clinical Activity of Afatinib in Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study
    Teresa Moran, Alvaro Taus, Edurne Arriola, Carlos Aguado, Manuel Dómine, Ana Gómez Rueda, Antonio Calles, Susana Cedrés, Nuria Viñolas, Dolores Isla, Ramón Palmero, María Sereno, Victor Diaz, Oscar Juan, Raquel Marsé, Paloma Martín Martorell, José Miguel
    Clinical Lung Cancer.2020; 21(5): 428.     CrossRef
  • HER2-positive advanced breast cancer treatment in 2020
    Marcelle G. Cesca, Lucas Vian, Sofia Cristóvão-Ferreira, Noam Pondé, Evandro de Azambuja
    Cancer Treatment Reviews.2020; 88: 102033.     CrossRef
  • New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?
    Essia Mezni, Cécile Vicier, Mathilde Guerin, Renaud Sabatier, François Bertucci, Anthony Gonçalves
    Cancers.2020; 12(6): 1573.     CrossRef
  • HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib
    Xinyong Zhang, Jialin Lv, Yuhua Wu, Na Qin, Li Ma, Xi Li, Jingying Nong, Hui Zhang, Quan Zhang, Xinjie Yang, Huibo Shi, Jinghui Wang, Shucai Zhang
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib
    Ji-Yeon Kim, Kyunghee Park, Seock-Ah Im, Kyung Hae Jung, Joohyuk Sohn, Keun Seok Lee, Jee Hyun Kim, Yaewon Yang, Yeon Hee Park
    Breast Cancer Research and Treatment.2020; 184(3): 743.     CrossRef
  • EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins
    Jordi Remon, Lizza E.L. Hendriks, Andres F. Cardona, Benjamin Besse
    Cancer Treatment Reviews.2020; 90: 102105.     CrossRef
  • Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma
    Giuseppe Lamberti, Elisa Andrini, Monia Sisi, Alessandro Rizzo, Claudia Parisi, Alessandro Di Federico, Francesco Gelsomino, Andrea Ardizzoni
    Critical Reviews in Oncology/Hematology.2020; 156: 103119.     CrossRef
  • Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer
    Xue Yang, Dapeng Wu, Shengli Yuan
    Technology in Cancer Research & Treatment.2020;[Epub]     CrossRef
  • Poziotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells
    Yongchao Zhang, Zhuo-Xun Wu, Yuqi Yang, Jing-Quan Wang, Jun Li, Zoey Sun, Qiu-Xu Teng, Charles R. Ashby, Dong-Hua Yang
    Cancers.2020; 12(11): 3249.     CrossRef
  • Role of Her-2 in Gastrointestinal Tumours beyond Gastric Cancer: A Tool for Precision Medicine
    Csongor G. Lengyel, Baker Habeeb, Shah Z. Khan, Khalid El Bairi, Sara C. Altuna, Sadaqat Hussain, Syed Ayub Mazher, Dario Trapani, Angelica Petrillo
    Gastrointestinal Disorders.2020; 3(1): 1.     CrossRef
  • Metastatic Breast Cancer Patient With Activating HER2 Exon 20 Insertion Mutation With Response to Poziotinib: Case Report of Compassionate Drug Use
    Apurva Pandey, Adam M. Brufsky
    Clinical Breast Cancer.2019; 19(1): e7.     CrossRef
  • Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry
    Debasis Das, Jian Hong
    European Journal of Medicinal Chemistry.2019; 170: 55.     CrossRef
  • Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer
    Wei Jiang, Meiju Ji
    Seminars in Cancer Biology.2019; 59: 3.     CrossRef
  • A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer
    Tae-Yong Kim, Hye Sook Han, Keun-Wook Lee, Dae Young Zang, Sun Young Rha, Young Iee Park, Jin-Soo Kim, Kyung-Hun Lee, Se Hoon Park, Eun-Kee Song, Soo-A Jung, NaMi Lee, Yeul Hong Kim, Jae Yong Cho, Yung-Jue Bang
    Gastric Cancer.2019; 22(6): 1206.     CrossRef
  • Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer
    Denis M. Collins, Neil T. Conlon, Srinivasaraghavan Kannan, Chandra S. Verma, Lisa D. Eli, Alshad S. Lalani, John Crown
    Cancers.2019; 11(6): 737.     CrossRef
  • Molecular alterations and poziotinib efficacy, a pan‐HER inhibitor, in human epidermal growth factor receptor 2 (HER2)‐positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2‐positi
    Ji‐Yeon Kim, Eunjin Lee, Kyunghee Park, Hae Hyun Jung, Woong‐Yang Park, Kyung‐Hun Lee, Joohyuk Sohn, Keun Seok Lee, Kyung Hae Jung, Jee Hyun Kim, Ki Hyeong Lee, Seock‐Ah Im, Yeon Hee Park
    International Journal of Cancer.2019; 145(6): 1669.     CrossRef
  • Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers
    Janakiraman Subramanian, Archana Katta, Ashiq Masood, Dashavantha Reddy Vudem, Rama Krishna Kancha
    The Oncologist.2019; 24(12): e1303.     CrossRef
  • Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study
    Takamasa Koga, Yoshihisa Kobayashi, Kenji Tomizawa, Kenichi Suda, Takayuki Kosaka, Yuichi Sesumi, Toshio Fujino, Masaya Nishino, Shuta Ohara, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Makoto Suzuki, Pasi A. Jänne, Tetsuya Mitsudomi
    Lung Cancer.2018; 126: 72.     CrossRef
  • A phase II trial of the pan‐HER inhibitor poziotinib, in patients with HER2‐positive metastatic breast cancer who had received at least two prior HER2‐directed regimens: results of the NOV120101‐203 trial
    Yeon Hee Park, Kyung‐Hun Lee, Joo Hyuk Sohn, Keun Seok Lee, Kyung Hae Jung, Jee‐Hyun Kim, Ki Hyeong Lee, Jin Seok Ahn, Tae‐Yong Kim, Gun Min Kim, In Hae Park, Sung‐Bae Kim, Se Hyun Kim, Hye Sook Han, Young‐Hyuck Im, Jin‐Hee Ahn, Jung‐Yong Kim, Jahoon Kang
    International Journal of Cancer.2018; 143(12): 3240.     CrossRef
  • EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas
    Susan E. Jorge, Antonio R. Lucena-Araujo, Hiroyuki Yasuda, Zofia Piotrowska, Geoffrey R. Oxnard, Deepa Rangachari, Mark S. Huberman, Lecia V. Sequist, Susumu S. Kobayashi, Daniel B. Costa
    Clinical Cancer Research.2018; 24(24): 6548.     CrossRef
  • 13,846 View
  • 689 Download
  • 62 Web of Science
  • 59 Crossref
Close layer
Experiences and Opinions Related to End-of-Life Discussion: From Oncologists' and Resident Physicians' Perspectives
Su-Jin Koh, Shinmi Kim, JinShil Kim, Bhumsuk Keam, Dae Seog Heo, Kyung Hee Lee, Bong-Seog Kim, Jee Hyun Kim, Hye Jung Chang, Sun Kyung Baek
Cancer Res Treat. 2018;50(2):614-623.   Published online July 3, 2017
DOI: https://doi.org/10.4143/crt.2016.446
AbstractAbstract PDFPubReaderePub
Purpose
The aims of this study were to explore how oncologists and resident physicians practice end-of-life (EOL) discussions and to solicit their opinions on EOL discussions as a means to improve the quality of EOL care.
Materials and Methods
A survey questionnaire was developed to explore the experiences and opinions about EOL discussions among oncologists and residents. Descriptive statistics, the t test, and the chisquare test were performed for the analyses.
Results
A total of 147 oncologists and 229 residents participated in this study. The study respondents reported diverse definitions of “terminal state,” and mostrespondents tried to disclose the patient’s condition to the patient and/or family members. Both groups were involved in EOL care discussions, with a rather low satisfaction level (57.82/100). The best timing to initiate discussionwas consideredwhen metastasis or disease recurrence occurred orwhen withdrawal of chemotherapy was anticipated. Furthermore, the study respondents suggested that patients and their family members should be included in the EOL discussion. Medical, legal, and ethical knowledge and communication difficulties along with practical issues were revealed as barriers and facilitators for EOL discussion.
Conclusion
This study explored various perspectives of oncologists and resident physicians for EOL discussion. Since the Life-Sustaining-Treatment Decision-Making Act will be implemented shortly in Korea, now is the time for oncologists and residents to prepare themselves by acquiring legal knowledge and communication skills. To achieve this, education, training, and clinical tools for healthcare professionals are required.

Citations

Citations to this article as recorded by  
  • Physicians are over optimistic in recognizing inpatients’ survival and palliative care needs: a large-scale multi-center study in Taiwan
    C -M Huang, S -J Huang, T -Y Wu, Y -C Chen, S -H Hsiao, D Chu
    QJM: An International Journal of Medicine.2024; 117(3): 195.     CrossRef
  • The quality of dying and death of patients with cancer from Shanghai in China from the perspective of healthcare providers: A cross-sectional study
    Jiawei Min, Peihao Liu, Kaifeng Xiao, Zhe Huang, Xiaobin Lai
    International Journal of Nursing Sciences.2024; 11(2): 179.     CrossRef
  • Issues and implications of the life-sustaining treatment decision act: comparing the data from the survey and clinical data of inpatients at the end-of-life process
    Eunjeong Song, Dongsoon Shin, Jooseon Lee, Seonyoung Yun, Minjeong Eom, Suhee Oh, Heejung Lee, Jiwan Lee, Rhayun Song
    BMC Medical Ethics.2024;[Epub]     CrossRef
  • Experience and perspectives of end-of-life care discussion and physician orders for life-sustaining treatment of Korea (POLST-K): a cross-sectional study
    Hyeon-Su Im, Insook Lee, Shinmi Kim, Jong Soo Lee, Ju-Hee Kim, Jae Young Moon, Byung Kyu Park, Kyung Hee Lee, Myung Ah Lee, Sanghoon Han, Yoonki Hong, Hyeyeoung Kim, Jaekyung Cheon, Su-Jin Koh
    BMC Medical Ethics.2023;[Epub]     CrossRef
  • Barriers and facilitators that hospital clinicians perceive to discuss the personal values, wishes, and needs of patients in palliative care: a mixed-methods systematic review
    Sita de Vries, Mary-Joanne Verhoef, Sigrid Cornelia Johanna Maria Vervoort, Yvette Milene van der Linden, Saskia Cornelia Constantia Maria Teunissen, Everlien de Graaf
    Palliative Care and Social Practice.2023;[Epub]     CrossRef
  • Association Among End-Of-Life Discussions, Cancer Patients’ Quality of Life at End of Life, and Bereaved Families’ Mental Health
    Yoko Hayashi, Kazuki Sato, Masahiro Ogawa, Yoshiro Taguchi, Hisashi Wakayama, Aya Nishioka, Chikako Nakamura, Kaoru Murota, Ayumi Sugimura, Shoko Ando
    American Journal of Hospice and Palliative Medicine®.2022; 39(9): 1071.     CrossRef
  • Difficulties Facing Junior Physicians and Solutions Toward Delivering End-of-Life Care for Patients with Cancer: A Nationwide Survey in Japan
    Soichiro Okamoto, Yu Uneno, Natsuki Kawashima, Shunsuke Oyamada, Yusuke Hiratsuka, Keita Tagami, Manabu Muto, Tatsuya Morita
    Palliative Medicine Reports.2022; 3(1): 255.     CrossRef
  • The silent transition from curative to palliative treatment: a qualitative study about cancer patients’ perceptions of end-of-life discussions with oncologists
    A. Kitta, A. Hagin, M. Unseld, F. Adamidis, T. Diendorfer, E. K. Masel, K. Kirchheiner
    Supportive Care in Cancer.2021; 29(5): 2405.     CrossRef
  • Advance Care Planning in Asia: A Systematic Narrative Review of Healthcare Professionals’ Knowledge, Attitude, and Experience
    Diah Martina, Cheng-Pei Lin, Martina S. Kristanti, Wichor M. Bramer, Masanori Mori, Ida J. Korfage, Agnes van der Heide, Carin C.D. van der Rijt, Judith A.C. Rietjens
    Journal of the American Medical Directors Association.2021; 22(2): 349.e1.     CrossRef
  • Difficulties Doctors Experience during Life-Sustaining Treatment Discussion after Enactment of the Life-Sustaining Treatment Decisions Act: A Cross-Sectional Study
    Shin Hye Yoo, Wonho Choi, Yejin Kim, Min Sun Kim, Hye Yoon Park, Bhumsuk Keam, Dae Seog Heo
    Cancer Research and Treatment.2021; 53(2): 584.     CrossRef
  • Changes in decision-making process for life-sustaining treatment in patients with advanced cancer after the life-sustaining treatment decisions-making act
    Hyeyeong Kim, Hyeon-Su Im, Kyong Og Lee, Young Joo Min, Jae-Cheol Jo, Yunsuk Choi, Yoo Jin Lee, Daseul Kang, Changyoung Kim, Su-Jin Koh, Jaekyung Cheon
    BMC Palliative Care.2021;[Epub]     CrossRef
  • Act on Decisions on Life-Sustaining Treatment and Timing of Referral to Hospice
    Han-na Ju, Seung Hun Lee, Yun-Jin Kim, Sang-Yeoup Lee, Jeong-Gyu Lee, Yu-Hyeon Yi, Young-Hye Cho, Young-Jin Tak, Hye-Rim Hwang, Eun-Ju Park, Young-In Lee
    Korean Journal of Family Practice.2021; 11(5): 331.     CrossRef
  • Nature of Discussions about Systemic Therapy Discontinuation or Hospice among Patients, Families, and Palliative Care Clinicians during Care for Incurable Cancer: A Qualitative Study
    Lara Traeger, Chelsea Rapoport, Emily Wright, Areej El-Jawahri, Joseph A. Greer, Elyse R. Park, Vicki A. Jackson, Jennifer S. Temel
    Journal of Palliative Medicine.2020; 23(4): 542.     CrossRef
  • Implication of the Life-Sustaining Treatment Decisions Act on End-of-Life Care for Korean Terminal Patients
    Jung Sun Kim, Shin Hye Yoo, Wonho Choi, Yejin Kim, Jinui Hong, Min Sun Kim, Hye Yoon Park, Bhumsuk Keam, Dae Seog Heo
    Cancer Research and Treatment.2020; 52(3): 917.     CrossRef
  • Advance care planning in Asian culture
    Shao-Yi Cheng, Cheng-Pei Lin, Helen Yue-lai Chan, Diah Martina, Masanori Mori, Sun-Hyun Kim, Raymond Ng
    Japanese Journal of Clinical Oncology.2020; 50(9): 976.     CrossRef
  • Differences in perspectives of pediatricians on advance care planning: a cross-sectional survey
    In Gyu Song, Sung Han Kang, Min Sun Kim, Cho Hee Kim, Yi Ji Moon, Jung Lee
    BMC Palliative Care.2020;[Epub]     CrossRef
  • Feasibility of a team based prognosis and treatment goal discussion (T-PAT) with women diagnosed with advanced breast cancer
    Mary M. Step, Gretchen A. Ferber, Catherine Downs-Holmes, Paula Silverman
    Patient Education and Counseling.2019; 102(1): 77.     CrossRef
  • Attitudes of the General Public, Cancer Patients, Family Caregivers, and Physicians Toward Advance Care Planning: A Nationwide Survey Before the Enforcement of the Life-Sustaining Treatment Decision-Making Act
    Hye Yoon Park, Young Ae Kim, Jin-Ah Sim, Jihye Lee, Hyewon Ryu, Jung Lim Lee, Chi Hoon Maeng, Jung Hye Kwon, Yu Jung Kim, Eun Mi Nam, Hyun-Jeong Shim, Eun-Kee Song, Kyung Hae Jung, Eun Joo Kang, Jung Hun Kang, Young Ho Yun
    Journal of Pain and Symptom Management.2019; 57(4): 774.     CrossRef
  • Family-clinician communication in the ICU and its relationship to psychological distress of family members: A cross-sectional study
    Minjeong Jo, Mi-Kyung Song, George J. Knafl, Linda Beeber, Yang-Sook Yoo, Marcia Van Riper
    International Journal of Nursing Studies.2019; 95: 34.     CrossRef
  • Implementation of Antimicrobial Stewardship Programs in End-of-Life Care
    Ki Tae Kwon
    Infection & Chemotherapy.2019; 51(2): 89.     CrossRef
  • Facilitators and Barriers to Oncologists’ Conduct of Goals of Care Conversations
    Dena Schulman-Green, Jenny J. Lin, Cardinale B. Smith, Shelli Feder, Nina A. Bickell
    Journal of Palliative Care.2018; 33(3): 143.     CrossRef
  • Clinical characteristics and survival outcomes of terminally ill patients undergoing withdrawal of mechanical ventilation
    Yu-Shin Hung, Shu-Hui Lee, Chia-Yen Hung, Chao-Hui Wang, Chen-Yi Kao, Hung-Ming Wang, Wen-Chi Chou
    Journal of the Formosan Medical Association.2017;[Epub]     CrossRef
  • 10,168 View
  • 268 Download
  • 22 Web of Science
  • 22 Crossref
Close layer
Epidemiology of Intracranial Metastases in Korea: A National Cohort Investigation
Tackeun Kim, Changhoon Song, Jung Ho Han, In-Ah Kim, Yu Jung Kim, Se Hyun Kim, Jee Hyun Kim, Chae-Yong Kim
Cancer Res Treat. 2018;50(1):164-174.   Published online March 21, 2017
DOI: https://doi.org/10.4143/crt.2017.072
AbstractAbstract PDFPubReaderePub
Purpose
To investigate the epidemiologic features of intracranial metastases (ICMET) in Korea, we performed a cohort study using the National Health Insurance Service–National Sample Cohort database, which comprised healthcare usage information of approximately 1 million Korean individuals over 12 years.
Materials and Methods
We enrolled 998,602 subjects, after excluding 18,218 subjects diagnosed with any cancer during the washout period (2002-2004). The observation period was 9 years (2005-2013; 8,725,438 person-years). The initial diagnosis date of ICMET and the primary cancer was recorded. The incidence was determined based on the number of incident cases and observation size, whereas survival was estimated using death statistics from the database.
Results
Through observation period, a total 776 subjects developed ICMET. The age-standardized incidence of ICMET was 8.2 per 100,000 person-years. The mean interval between the initial diagnosis date of the primary cancer and ICMET was 13.1 months. Patients with ICMET had shorter survival than those without ICMET (30.9 months vs. 81.4 months, p < 0.001). The ICMET incidence among the cancer patients was 5.0 per 1,000 personyears; it was highest in lung cancer cases, followed by breast and liver cancer cases. Moreover, ICMET from lung cancer was the most common metastasis type, followed by ICMET from liver and breast cancer.
Conclusion
The incidence of ICMET was 8.2 per 100,000 person-years among the Korean population and 5.0 per 1,000 person-years among cancer patients. Most of the ICMET cases arose from lung cancer. ICMET also critically influenced survival in cancer patients.

Citations

Citations to this article as recorded by  
  • TRP-2 / gp100 DNA vaccine and PD-1 checkpoint blockade combination for the treatment of intracranial tumors
    Joshua R. D. Pearson, Carles Puig-Saenz, Jubini E. Thomas, Lydia D. Hardowar, Murrium Ahmad, Louise C. Wainwright, Adam M. McVicar, Victoria A. Brentville, Chris J. Tinsley, A. Graham Pockley, Lindy G. Durrant, Stephanie E. B. McArdle
    Cancer Immunology, Immunotherapy.2024;[Epub]     CrossRef
  • Dural Metastasis in Breast Cancer: MRI-Based Morphological Subtypes and Their Clinical Implications
    Sung Jun Ahn, Bio Joo, Mina Park, Hun Ho Park, Sang Hyun Suh, Sung Gwe Ahn, Jihwan Yoo
    Cancer Research and Treatment.2024; 56(4): 1105.     CrossRef
  • Treatment Outcome of the Brain Metastases in Peri-Rolandic Area: Comparison Between Surgery and Stereotactic Radiosurgery
    Jun Hyeok Jung, Kawngwoo Park, Eun Young Kim, Chan-Jong Yoo, Gi-Taek Yee, Woo-Kyung Kim, Dong-Won Shin
    Brain Tumor Research and Treatment.2023; 11(4): 246.     CrossRef
  • Mutational profiles of primary pulmonary adenocarcinoma and paired brain metastases disclose the importance of KRAS mutations
    Erik Vassella, Elham Kashani, Philipp Zens, Alexandra Kündig, Christian Fung, Amina Scherz, Evelyn Herrmann, Ekin Ermis, Ralph A. Schmid, Sabina Berezowska
    European Journal of Cancer.2021; 159: 227.     CrossRef
  • Verification of Low Risk for Perihippocampal Recurrence in Patients with Brain Metastases Who Received Whole-Brain Radiotherapy with Hippocampal Avoidance
    Youngkyong Kim, Sung Hwan Kim, Jong Hoon Lee, Dae Gyu Kang
    Cancer Research and Treatment.2019; 51(2): 568.     CrossRef
  • Non–coplanar whole brain radiotherapy is an effective modality for parotid sparing
    Jaehyeon Park, Jae Won Park, Ji Woon Yea
    Yeungnam University Journal of Medicine.2019; 36(1): 36.     CrossRef
  • Whole brain radiotherapy using four-field box technique with tilting baseplate for parotid gland sparing
    Jaehyeon Park, Ji Woon Yea
    Radiation Oncology Journal.2019; 37(1): 22.     CrossRef
  • 9,516 View
  • 238 Download
  • 5 Web of Science
  • 7 Crossref
Close layer
Bilateral Salpingo-oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor–Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors
Koung Jin Suh, Se Hyun Kim, Kyung-Hun Lee, Tae-Yong Kim, Yu Jung Kim, Sae-Won Han, Eunyoung Kang, Eun-Kyu Kim, Kidong Kim, Jae Hong No, Wonshik Han, Dong-Young Noh, Maria Lee, Hee Seung Kim, Seock-Ah Im, Jee Hyun Kim
Cancer Res Treat. 2017;49(4):1153-1163.   Published online February 27, 2017
DOI: https://doi.org/10.4143/crt.2016.463
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Although combining aromatase inhibitors (AI) with gonadotropin-releasing hormone agonists (GnRHa) is becoming more common, it is still not clear if GnRHa is as effective as bilateral salpingo-oophorectomy (BSO).
Materials and Methods
We retrospectively analyzed data of 66 premenopausal patients with hormone receptor– positive, human epidermal growth factor receptor 2–negative recurrent and metastatic breast cancer who had been treated with AIs in combination with GnRHa or BSO between 2002 and 2015.
Results
The median patient age was 44 years. Overall, 24 (36%) received BSO and 42 (64%) received GnRHa. The clinical benefit rate was higher in the BSO group than in the GnRHa group (88% vs. 69%, p=0.092). Median progression-free survival (PFS) was longer in the BSO group, although statistical significance was not reached (17.2 months vs. 13.3 months, p=0.245). When propensity score matching was performed, the median PFS was 17.2 months for the BSO group and 8.2 months for the GnRHa group (p=0.137). Multivariate analyses revealed that the luminal B subtype (hazard ratio, 1.67; 95% confidence interval [CI], 1.08 to 2.60; p=0.022) and later-line treatment (≥ third line vs. first line; hazard ratio, 3.24; 95% CI, 1.59 to 6.59; p=0.001) were independent predictive factors for a shorter PFS. Incomplete ovarian suppression was observed in a subset of GnRHa-treated patients whose disease showed progression, with E2 levels higher than 21 pg/mL.
Conclusion
Both BSO and GnRHa were found to be effective in our AI-treated premenopausal metastatic breast cancer patient cohort. However, further studies in larger populations are needed to determine if BSO is superior to GnRHa.

Citations

Citations to this article as recorded by  
  • Incomplete ovarian function suppression in premenopausal breast cancer patients treated with gonadotropin-releasing hormone agonists
    Jinna Lin, Shuqi Zheng, Qiang Liu
    Cancer Treatment Reviews.2025; 133: 102879.     CrossRef
  • Effectiveness of gonadotropin-releasing hormone agonists for ovarian function suppression in premenopausal patients with hormone receptor-positive breast cancer: a retrospective single-center real-world study
    Yifei Chen, Ruyan Zhang, Ying Yan, Huiping Li, Guohong Song
    Breast Cancer Research and Treatment.2024; 206(3): 543.     CrossRef
  • Oophorectomy in Premenopausal Patients with Estrogen Receptor-Positive Breast Cancer: New Insights into Long-Term Effects
    Fatima Khan, Kristin Rojas, Matthew Schlumbrecht, Patricia Jeudin
    Current Oncology.2023; 30(2): 1794.     CrossRef
  • Comparison of outcomes in patients with luminal type breast cancer treated with a gonadotropin-releasing hormone analog or bilateral salpingo-oophorectomy: A cohort retrospective study
    Dwi Ris Andriyanto, Prihantono, Salman Ardi Syamsu, Muhammad Ihwan Kusuma, Joko Hendarto, Indra, Nilam Smaradania, Elridho Sampepajung, Asrul Mappiwali, Muhammad Faruk
    Annals of Medicine & Surgery.2022;[Epub]     CrossRef
  • Awareness of the Causes Leading to Surgical Ablation of Ovarian Function in Premenopausal Breast Cancer—A Single-Center Analysis
    Joana Correia Oliveira, Filipa Costa Sousa, Inês Gante, Margarida Figueiredo Dias
    Medicina.2021; 57(4): 385.     CrossRef
  • Long-term effect of repeated deslorelin acetate treatment in bitches for reproduction control
    Brändli SP, Palm J, Kowalewski MP, Reichler IM
    Theriogenology.2021; 173: 73.     CrossRef
  • Prognostic Factors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2–) Advanced Breast Cancer: A Systematic Literature Review
    Gebra Cuyún Carter, Maitreyee Mohanty, Keri Stenger, Claudia Morato Guimaraes, Shivaprasad Singuru, Pradeep Basa, Sheena Singh, Vanita Tongbram, Sherko Kuemmel, Valentina Guarneri, Sara M Tolaney
    Cancer Management and Research.2021; Volume 13: 6537.     CrossRef
  • Oophorectomy as a Hormonal Ablation Therapy in Metastatic and Recurrent Breast Cancer: Current Indications and Results
    Islam H. Metwally, Omar Hamdy, Saleh S. Elbalka, Mohamed Elbadrawy, Dina M. Elsaid
    Indian Journal of Surgical Oncology.2019; 10(3): 542.     CrossRef
  • Targeted Therapy for Premenopausal Women with HR+, HER2− Advanced Breast Cancer: Focus on Special Considerations and Latest Advances
    Aditya Bardia, Sara Hurvitz
    Clinical Cancer Research.2018; 24(21): 5206.     CrossRef
  • 12,968 View
  • 367 Download
  • 12 Web of Science
  • 9 Crossref
Close layer
CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy
Dae-Won Lee, Seock-Ah Im, Yu Jung Kim, Yaewon Yang, Jiyoung Rhee, Im Il Na, Kyung-Hun Lee, Tae-Yong Kim, Sae-Won Han, In Sil Choi, Do-Youn Oh, Jee Hyun Kim, Tae-You Kim, Yung-Jue Bang
Cancer Res Treat. 2017;49(3):807-815.   Published online January 18, 2017
DOI: https://doi.org/10.4143/crt.2016.326
AbstractAbstract PDFPubReaderePub
Purpose
While tumor markers (carbohydrate antigen 19-9 [CA 19-9] and carcinoembryonic antigen [CEA]) can aid in the diagnosis of biliary tract cancer, their prognostic role has not been clearly elucidated. Therefore, this study was conducted to evaluate the prognostic role of tumor markers and tumor marker change in patients with advanced biliary tract cancer.
Materials and Methods
Patients with pathologically proven metastatic or relapsed biliary tract cancer who were treated in a phase II trial of first-line S-1 and cisplatin chemotherapy were enrolled. Serum tumor markers were measured at baseline and after the first cycle of chemotherapy.
Results
Among a total of 104 patients, 80 (77%) had elevated baseline tumor markers (69 with CA 19-9 elevation and 40 with CEA). A decline ≥ 30% of the elevated tumor marker level after the first cycle of chemotherapy conferred an improved time to progression (TTP), overall survival (OS), and better chemotherapy response. Multivariate analysis revealed tumor marker decline as an independent positive prognostic factor of TTP (adjusted hazard ratio [HR], 0.44; p=0.003) and OS (adjusted HR, 0.37; p < 0.001). Subgroup analysis revealed similar results in each group of patients with CA 19-9 elevation and CEA elevation. In addition, elevated baseline CEA was associated with poor survival in both univariate and multivariate analysis.
Conclusion
Tumor marker decline was associated with improved survival in biliary tract cancer. Measuring tumor marker after the first cycle of chemotherapy can be used as an early assessment of treatment outcome.

Citations

Citations to this article as recorded by  
  • Clinical epidemiology of gallbladder cancer in North-Central India and association of immunological markers, NLR, MLR and PLR in the diagnostic/prognostic prediction of GBC
    Jyotsna Singh, Durgesh Shukla, Sanjiv Gupta, Braj Raj Shrivastav, Pramod Kumar Tiwari
    Cancer Treatment and Research Communications.2021; 28: 100431.     CrossRef
  • Neoadjuvant Intraperitoneal Chemotherapy in Patients with Pseudomyxoma Peritonei—A Novel Treatment Approach
    Aruna Prabhu, Andreas Brandl, Satoshi Wakama, Shouzou Sako, Haruaki Ishibashi, Akiyoshi Mizumoto, Nobuyuki Takao, Kousuke Noguchi, Shunsuke Motoi, Masumi Ichinose, Yang Liu, Yutaka Yonemura
    Cancers.2020; 12(8): 2212.     CrossRef
  • Clinical and Translational Research Challenges in Biliary Tract Cancers
    Angela Lamarca, Melissa Frizziero, Mairéad G. McNamara, Juan W. Valle
    Current Medicinal Chemistry.2020; 27(29): 4756.     CrossRef
  • Therapeutic outcomes and prognostic factors in unresectable gallbladder cancer treated with gemcitabine plus cisplatin
    Min su You, Ji Kon Ryu, Young Hoon Choi, Jin Ho Choi, Gunn Huh, Woo Hyun Paik, Sang Hyub Lee, Yong-Tae Kim
    BMC Cancer.2019;[Epub]     CrossRef
  • Efficacy of interventional therapy and effect on inflammatory factors in patients with gastric cancer after chemotherapy
    Puzhao Wu, Jing Wang
    Oncology Letters.2019;[Epub]     CrossRef
  • CA19-9 kinetics during systemic chemotherapy in patients with advanced or recurrent biliary tract cancer
    Naminatsu Takahara, Yousuke Nakai, Hiroyuki Isayama, Takashi Sasaki, Kei Saito, Kensaku Noguchi, Tatsunori Suzuki, Tomoka Nakamura, Tatsuya Sato, Kazunaga Ishigaki, Ryunosuke Hakuta, Tsuyoshi Takeda, Rie Uchino, Suguru Mizuno, Hirofumi Kogure, Minoru Tada
    Cancer Chemotherapy and Pharmacology.2017; 80(6): 1105.     CrossRef
  • 13,178 View
  • 203 Download
  • 7 Web of Science
  • 6 Crossref
Close layer
Antitumor Effect of KX-01 through Inhibiting Src Family Kinases and Mitosis
Seongyeong Kim, Ahrum Min, Kyung-Hun Lee, Yaewon Yang, Tae-Yong Kim, Jee Min Lim, So Jung Park, Hyun-Jin Nam, Jung Eun Kim, Sang-Hyun Song, Sae-Won Han, Do-Youn Oh, Jee Hyun Kim, Tae-You Kim, David Hangauer, Johnson Yiu-Nam Lau, Kyongok Im, Dong Soon Lee, Yung-Jue Bang, Seock-Ah Im
Cancer Res Treat. 2017;49(3):643-655.   Published online October 6, 2016
DOI: https://doi.org/10.4143/crt.2016.168
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
KX-01 is a novel dual inhibitor of Src and tubulin. Unlike previous Src inhibitors that failed to show clinical benefit during treatment of breast cancer, KX-01 can potentially overcome the therapeutic limitations of current Src inhibitors through inhibition of both Src and tubulin. The present study further evaluates the activity and mechanism of KX-01 in vitro and in vivo.
Materials and Methods
The antitumor effect of KX-01 in triple negative breast cancer (TNBC) cell lines was determined by MTT assay. Wound healing and immunofluorescence assays were performed to evaluate the action mechanisms of KX-01. Changes in the cell cycle and molecular changes induced by KX-01 were also evaluated. A MDA-MB-231 mouse xenograft model was used to demonstrate the in vivo effects.
Results
KX-01 effectively inhibited the growth of breast cancer cell lines. The expression of phospho- Src and proliferative-signaling molecules were down-regulated in KX-01–sensitive TNBC cell lines. In addition, migration inhibition was observed by wound healing assay. KX-01– induced G2/M cell cycle arrest and increased the aneuploid cell population in KX-01–sensitive cell lines. Multi-nucleated cells were significantly increased after KX-01 treatment. Furthermore, KX-01 effectively delayed tumor growth in a MDA-MB-231 mouse xenograft model.
Conclusion
KX-01 effectively inhibited cell growth and migration of TNBC cells. Moreover, this study demonstrated that KX-01 showed antitumor effects through the inhibition of Src signaling and the induction of mitotic catastrophe. The antitumor effects of KX-01 were also demonstrated in vivo using a mouse xenograft model.

Citations

Citations to this article as recorded by  
  • Clinical and experimental aspects of tirbanibulin treatments
    Annabel Shen, Rebecca A. Simonette, Peter L. Rady, Stephen K. Tyring
    Archives of Dermatological Research.2025;[Epub]     CrossRef
  • The Potential Strategies for Overcoming Multidrug Resistance and Reducing Side Effects of Monomer Tubulin Inhibitors for Cancer Therapy
    Yingjie Cui, Jing Zhang, Guifang Zhang
    Current Medicinal Chemistry.2024; 31(14): 1874.     CrossRef
  • Efficacy and tolerability of tirbanibulin 1% ointment in the treatment of cancerization field: a real‐life Italian multicenter observational study of 250 patients
    Gianluca Nazzaro, Andrea Carugno, Paolo Bortoluzzi, Stefano Buffon, Chiara Astrua, Elena Zappia, Emanuele Trovato, Stefano Caccavale, Vincenzo Pellegrino, Giovanni Paolino, Riccardo Balestri, Rossella Lacava, Giulia Ciccarese, Alice Verdelli, Stefania Bar
    International Journal of Dermatology.2024; 63(11): 1566.     CrossRef
  • Dickkopf-1 (DKK1) drives growth and metastases in castration-resistant prostate cancer
    Letizia Rinella, Gloria Fiorentino, Mara Compagno, Cristina Grange, Massimo Cedrino, Francesca Marano, Ornella Bosco, Elena Vissio, Luisa Delsedime, Patrizia D’Amelio, Benedetta Bussolati, Emanuela Arvat, Maria Graziella Catalano
    Cancer Gene Therapy.2024; 31(8): 1266.     CrossRef
  • Anti-tumor effects of tirbanibulin in squamous cell carcinoma cells are mediated via disruption of tubulin-polymerization
    Viola K. DeTemple, Antje Walter, Sabine Bredemeier, Ralf Gutzmer, Katrin Schaper-Gerhardt
    Archives of Dermatological Research.2024;[Epub]     CrossRef
  • Tirbanibulin decreases cell proliferation and downregulates protein expression of oncogenic pathways in human papillomavirus containing HeLa cells
    Stephen Moore, Veda Kulkarni, Angela Moore, Jennifer R. Landes, Rebecca Simonette, Qin He, Peter L. Rady, Stephen K. Tyring
    Archives of Dermatological Research.2024;[Epub]     CrossRef
  • Topical Pharmacological Treatment of Actinic Keratoses: Focus on Tirbanibulin 1% Ointment
    Mario Valenti, Matteo Bianco, Alessandra Narcisi, Antonio Costanzo, Riccardo Borroni, Marco Ardigò
    Dermatology Practical & Conceptual.2024; 14(S1): e2024145S.     CrossRef
  • Recent advancement in developing small molecular inhibitors targeting key kinase pathways against triple-negative breast cancer
    Rajibul Islam, Khor Poh Yen, Nur Najihah ’Izzati Mat Rani, Md. Selim Hossain
    Bioorganic & Medicinal Chemistry.2024; 112: 117877.     CrossRef
  • Real-world experience with histological confirmation of clinical response of squamous cell carcinoma to topical tirbanibulin
    Angela Moore, Kara Hurley, Stephen A. Moore, Luke Moore
    JAAD Case Reports.2023; 40: 141.     CrossRef
  • Synthesis and evaluation of tirbanibulin derivatives: a detailed exploration of the structure–activity relationship for anticancer activity
    Jaebeom Park, Minji Kang, Ahyoung Lim, Kyung-Jin Cho, Chong Hak Chae, Byumseok Koh, Hongjun Jeon
    RSC Advances.2023; 13(50): 35583.     CrossRef
  • Tirbanibulina: revisión de su mecanismo de acción novedoso y de cómo encaja en el tratamiento de la queratosis actínica
    Y. Gilaberte, M.T. Fernández-Figueras
    Actas Dermo-Sifiliográficas.2022; 113(1): 58.     CrossRef
  • Insights on Cancer Cell Inhibition, Subcellular Activities, and Kinase Profile of Phenylacetamides Pending 1H-Imidazol-5-One Variants
    Maan T. Khayat, Abdelsattar M. Omar, Farid Ahmed, Mohammad I. Khan, Sara M. Ibrahim, Yosra A. Muhammad, Azizah M. Malebari, Thikryat Neamatallah, Moustafa E. El-Araby
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Identification of New Vulnerabilities in Conjunctival Melanoma Using Image-Based High Content Drug Screening
    Katya Nardou, Michael Nicolas, Fabien Kuttler, Katarina Cisarova, Elifnaz Celik, Mathieu Quinodoz, Nicolo Riggi, Olivier Michielin, Carlo Rivolta, Gerardo Turcatti, Alexandre Pierre Moulin
    Cancers.2022; 14(6): 1575.     CrossRef
  • Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies
    Minru Liao, Rui Qin, Wei Huang, Hong-Ping Zhu, Fu Peng, Bo Han, Bo Liu
    Journal of Hematology & Oncology.2022;[Epub]     CrossRef
  • SAR Probing of KX2-391 Provided Analogues With Juxtaposed Activity Profile Against Major Oncogenic Kinases
    Abdelsattar M. Omar, Maan T. Khayat, Farid Ahmed, Yosra A. Muhammad, Azizah M. Malebari, Sara M. Ibrahim, Mohammad I. Khan, Dhaval K. Shah, Wayne E. Childers, Moustafa E. El-Araby
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Topical Tirbanibulin, a Dual Src Kinase and Tubulin Polymerization Inhibitor, for the Treatment of Plaque-Type Psoriasis: Phase I Results
    Jin-Bon Hong, Po-Yuan Wu, Albert Qin, Yi-Wen Huang, Kuan-Chiao Tseng, Ching-Yu Lai, Wing-Kai Chan, Jane Fang, David L. Cutler, Tsen-Fang Tsai
    Pharmaceutics.2022; 14(10): 2159.     CrossRef
  • Tirbanibulin for Actinic Keratosis: Insights into the Mechanism of Action
    Todd Schlesinger, Eggert Stockfleth, Ayman Grada, Brian Berman
    Clinical, Cosmetic and Investigational Dermatology.2022; Volume 15: 2495.     CrossRef
  • Dual Kinase Targeting in Leukemia
    Luca Mologni, Giovanni Marzaro, Sara Redaelli, Alfonso Zambon
    Cancers.2021; 13(1): 119.     CrossRef
  • Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy
    Wen Shuai, Guan Wang, Yiwen Zhang, Faqian Bu, Sicheng Zhang, Duane D. Miller, Wei Li, Liang Ouyang, Yuxi Wang
    Journal of Medicinal Chemistry.2021; 64(12): 7963.     CrossRef
  • New FDA oncology small molecule drugs approvals in 2020: Mechanism of action and clinical applications
    Thais Cristina Mendonça Nogueira, Marcus Vinicius Nora de Souza
    Bioorganic & Medicinal Chemistry.2021; 46: 116340.     CrossRef
  • Tirbanibulin: review of its novel mechanism of action and how it fits into the treatment of actinic keratosis
    Y. Gilaberte, M.T. Fernández-Figueras
    Actas Dermo-Sifiliográficas (English Edition).2021;[Epub]     CrossRef
  • Recent progress in small molecule agents for the targeted therapy of triple-negative breast cancer
    Rajibul Islam, Kok Wai Lam
    European Journal of Medicinal Chemistry.2020; 207: 112812.     CrossRef
  • Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy
    Kinsie E Arnst, Souvik Banerjee, Hao Chen, Shanshan Deng, Dong‐Jin Hwang, Wei Li, Duane D Miller
    Medicinal Research Reviews.2019; 39(4): 1398.     CrossRef
  • Reversible binding of the anticancer drug KXO1 (tirbanibulin) to the colchicine-binding site of β-tubulin explains KXO1's low clinical toxicity
    Lu Niu, Jianhong Yang, Wei Yan, Yamei Yu, Yunhua Zheng, Haoyu Ye, Qiang Chen, Lijuan Chen
    Journal of Biological Chemistry.2019; 294(48): 18099.     CrossRef
  • Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361)
    Michael P. Smolinski, Yahao Bu, James Clements, Irwin H. Gelman, Taher Hegab, David L. Cutler, Jane W. S. Fang, Gerald Fetterly, Rudolf Kwan, Allen Barnett, Johnson Y. N. Lau, David G. Hangauer
    Journal of Medicinal Chemistry.2018; 61(11): 4704.     CrossRef
  • KX2-361: a novel orally bioavailable small molecule dual Src/tubulin inhibitor that provides long term survival in a murine model of glioblastoma
    Michael J. Ciesielski, Yahao Bu, Stephan A. Munich, Paola Teegarden, Michael P. Smolinski, James L. Clements, Johnson Y. N. Lau, David G. Hangauer, Robert A. Fenstermaker
    Journal of Neuro-Oncology.2018; 140(3): 519.     CrossRef
  • 15,390 View
  • 385 Download
  • 24 Web of Science
  • 26 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP